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2.1 DIABETES 
Diabetes mellitus, is a major epidemic of this century (Shaw et al., 2010), 
which has increased in incidence by 50% over the past 10 years (Danaei et 
al., 2011). The World Health Organization states that 347 million people 
worldwide were suffering from diabetes in 2008, which equates to 9.5% of 
the adult population (Danaei et al., 2011). The incidence of diabetes is 
increasing rapidly with estimations and this number will almost double by 
2030. Diabetes mellitus is more common in developed countries but occurs 
throughout the world. In the near future there will be the greatest increase 
but a large spread of pathology, however, is expected to occur in 
developing countries where there will be ~50% increase in diabetes by 2030 
(Shaw et al., 2010). 
Diabetes is clinically characterized by hyperglycemia due to chronic 
and/or relative insulin insufficiency (Mathis et al., 2001). In Diabetes Mellitus, 
also known as type 1 diabetes, hyperglycemia occurs as a result of a 
complex pathological process where the pancreatic beta-cells within the 
islets of Langerhans are destroyed due to genetic and environmental 
factors that lead to an autoimmune response (Davies et al., 1994). This 
process results in individuals relying essentially on exogenous insulin 
administration for survival. The genetic basis of this disease is not yet fully 
understood. Indeed, a number of major genetic determinants of type 1 
diabetes such as alleles of the major histocompatibility locus (HLA) at the 
HLA-DRB1 and DQB1 loci (Nejentsev et al., 2007) and more recently the 
HLA-B*39 locus (Hyttinen et al., 2003) only account for some 40–50% of the 
familial clustering of this disorder. This suggests that there are other genetic 
loci involved in susceptibility to type 1 diabetes. The rising incidence of this 
pathology may also be influenced by insulin resistance, which has been 
reported as a risk factor for type 1 diabetes (Fourlanos et al., 2004). 
Although type 1 diabetes is an insulin-deficient state, features of insulin 
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resistance are increasingly common, with the high prevalence of obesity in 
Westernized populations.  
COMPLICATIONS OF DIABETES 
Diabetes is associated with many complications. Acute metabolic 
complications associated with mortality include diabetic ketoacidosis from 
exceptionally high blood glucose concentrations (hyperglycemia) and 
coma as the result of low blood glucose (hypoglycemia). In diabetes, the 
resulting complications are grouped under “microvascular disease” (due to 
damage to small blood vessels) and “macrovascular disease” (due to 
damage to the arteries). Microvascular complications include eye disease 
or “retinopathy,” kidney disease termed “nephropathy,” and neural 
damage or “neuropathy”. The major macrovascular complications include 
accelerated cardiovascular disease resulting in myocardial infarction and 
cerebrovascular disease manifesting as strokes. Other chronic 
complications of diabetes include depression, (Nouwen et al., 2011), 
dementia (Cukierman et al., 2005), and sexual dysfunction (Thorve et al., 
2011). 
DIABETIC NEUROPATHY 
Peripheral nervous system (PNS) damage (i.e., diabetic neuropathy) is the 
most frequent symptomatic complication characterized by a spectrum of 
functional and structural changes in peripheral nerves including axonal 
degeneration, paranodal demyelination and loss of myelinated fibers and 
decreased nerve conduction velocity (Sugimoto et al., 2000, Vinik et al., 
2000). More than 50% of diabetic subjects eventually develop neuropathy 
(Abbott et al., 2011), with a lifetime risk of extremity amputations. Diabetic 
neuropathy is a syndrome that hits both the somatic and autonomic 
divisions of the peripheral nervous system. There is, however, a growing 
appreciation that damage to the spinal cord (Selvarajah et al., 2006) and 
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the higher central nervous system (Wessels et al., 2006) can also occur and 
that neuropathy is a major factor in the impaired wound healing, erectile 
dysfunction, and cardiovascular dysfunction seen in diabetes. Disease 
progression in neuropathy was traditionally clinically characterized by the 
development of vascular abnormalities with subsequent hypoxia. Inhibitors 
of the renin-angiotensin system and α1-antagonists improve nerve 
conduction velocities in the clinical context, which is postulated to be a 
result of increases in neuronal blood flow. Advanced neuropathy due to 
nerve fiber deterioration in diabetes is characterized by altered sensitivities 
to vibrations and thermal thresholds, which bring to loss of peripheral 
sensitivity. Hyperalgesia, paresthesias, and allodynia also occur in a 
proportion of patients, with pain evident in 40–50% of those with diabetic 
neuropathy. Recently, however, there has been some controversy as to the 
inclusion of neuropathy as a “microvascular” complication, given that 
changes in neuronal blood vessels are considered by some investigators to 
be a secondary effect of an underlying neuronal and glial disorder 
associated with neuropathy rather than the vasculopathy being implicated 
as the cause of this group of complications. Indeed, recently there is some 
evidence suggesting that diabetic neuropathy selectively targets sensory 
and autonomic neurons over motor neurons, with little vascular 
involvement. (Forbes and Cooper, 2013) 
The size of neurons is also important. It appears that in diabetes, longer 
nerve fibers show an earlier loss of nerve conduction velocity with loss of 
their nerve terminals. This is the reason why tingling and loss of sensation and 
reflexes are often first observed in the feet and then ascend to affect other 
areas, in particular the hands. This syndrome includes numbness, 
dysesthesia (pins and needles), sensory loss, and nighttime pain; early in the 
disease progression, also spatial awareness of limb location is affected. This 
includes a loss of sensation in response to injury leading to a high risk of 
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developing foot and leg ulcers, which can ultimately result in amputation. 
Some diabetic subjects can also incurr in multiple fractures and they can 
develop a Charcot joint, a degenerative condition characterized by loss in 
bone volume and eventually deformity. Progressive motor dysfunction is 
also common in diabetic neuropathy, which can lead to dorsiflexion of the 
digits of the hands and toes. In addition to motor neuron dysfunction, the 
autonomic nervous system is also influenced by diabetes. Common 
diabetes related abnormalities in autonomic function are: orthostatic 
hypotension, due to an inability to adjust heart rate and vascular tone to 
maintain blood flow to the brain and gastroparesis, nausea and bloating, 
that affect autonomic nerves innervating the gastrointestinal tract leading 
to altered efficacy of oral medications. In particular, delayed gastric 
emptying can dramatically affect glycemic control by delaying the 
absorption of key nutrients, as well as antidiabetic agents leading to 
imbalances in glucose homeostasis. In diabetes the duration of pathology 
and lack of glycemic control, consistent with other complications, are the 
major risk factors for neuropathy (1993). Other than optimization of 
glycemic control and management of neuropathic pain, there are no 
major therapies approved in either Europe or the United States for the 
treatment of diabetic neuropathy. In addition, as is seen with other 
complications, the mechanisms leading to diabetic neuropathy are poorly 
understood. At present, treatment generally focuses on alleviation of pain, 
but the process is generally progressive.  
A possible clue to identify putative targets for a more effective treatment 
would be the identification of relevant molecular events occurring in the 
peripheral nerves under physiologic and pathologic conditions.  
Experimental diabetic neuropathy and experimental diabetic 
encephalopathy show similar features to human complications (Alvarez et 
al., 2009, Beauquis et al., 2006). Recent findings from experimental models 
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of diabetic neuropathy and diabetic encephalopathy indicate that, at 
least in male rats, neuroactive steroids are protective agents (Roglio et al., 
2007). The term neuroactive steroids defines steroids acting in the nervous 
system and includes molecules produced by the nervous system 
(neurosteroids) and hormonal compounds deriving from classical 
steroidogenic tissues (i.e., gonads and adrenal glands). Moreover, 
peripheral nerves express receptors for neuroactive steroids and 
consequently represent a target for them. For instance, treatment with 
progesterone (PROG), or its 5alpha-reduced metabolite, 
dihydroprogesterone (DHP), counteracts the increase in the number of 
fibers with myelin infoldings observed in the sciatic nerve of 
streptozotocin(STZ)-treated rat (Veiga et al., 2006b). Moreover, neuroactive 
steroids, such as PROG, testosterone (T) and their derivatives (e.g., DHP and 
tetrahydroprogesterone, THP, in the case of PROG; dihydrotestosterone, 
DHT, and 3α-diol, in the case of T), or dehydroepiandrosterone (DHEA) 
influence a variety of biochemical and functional parameters, including 
nerve conduction velocity, thermal threshold, skin innervation density, 
Na+,K+-ATPase activity and expression of myelin proteins, which are 
affected in STZ-treated rat (Leonelli et al., 2007, Roglio et al., 2007, Yorek et 
al., 2002). 
Reduced nerve conduction velocity and increased thermal nociceptive 
response in diabetic peripheral neuropathy is associated with myelin 
alterations, (Herman, 2007). Similar structural abnormalities and 
neurophysiological changes have been observed in the peripheral nerves 
of streptozotocin (STZ)-treated rats, an experimental model that captures 
many features of type 1 diabetes (Biessels et al., 1999, Dyck et al., 1988). As 
it is seen in diabetic subjects, STZ-treated rats show increased 
morphological alterations in the myelinated fibers of the sciatic nerve 
(Veiga et al., 2006a). 
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Recently, it has been reported that in BB/Wor diabetic rats, type 1 diabetes 
reduces the expression of the lipogenic transcription factor sterol-regulatory 
element binding factor-1c (SREBP-1c) in Schwann cells (de Preux et al., 
2007). It has also been shown that the acute phase of myelin lipid synthesis 
is regulated by SREBP cleavage activating protein (SCAP), an activator of 
SREBPs (Verheijen et al., 2009). These observations suggest that lack of 
insulin and/or of transcriptionally active SREBP-1c in peripheral nerves leads 
to decreased lipogenesis. Diminished or abnormal FA synthesis may play an 
important role in altered myelin lipid and protein composition. Such 
changes in myelin could affect membrane fluidity and function, ultimately 
contributing to the pathogenesis of DPN (Verheijen et al., 2009, Zuvic-
Butorac et al., 2001). In support of this notion, studies in animal models have 
revealed a protective effect of administration of FAs on DPN (Coste et al., 
2004). 
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2.2 MYELIN 
Structural abnormalities and neurophysiological changes have been 
observed in the peripheral nerves of STZ-treated rats, an experimental 
model that captures many features of type 1 diabetes (Dyck et al., 1988). 
As described before the diabetic peripheral neuropathy induced by 
diabetes is associated with deleterious changes in peripheral nerves, such 
as decrease in nerve conduction velocity and myelin damage (Sugimoto 
et al., 2000, Valls-Canals et al., 2002).  
The principal role of the myelin sheath is to allow the faster transmission of 
the nervous impulse along the axons, which it surrounds. It accomplishes this 
function in the same way as the insulation around an electrical wire lets 
electricity flow through the wire, by preventing its dissipation into the 
surrounding medium. The membrane of the myelinated axon expresses 
numerous physiologically active molecules, which intervene directly in the 
transmission of the nervous impulse. These include the voltage-sensitive 
sodium channels, that are directly responsible for the propagation of the 
action potential along the axon and that are concentrated at the non-
insulated axonal segments, known as the nodes of Ranvier, as well as the 
fast and slow potassium channels responsible for various secondary 
electrophysiological activities involved in the recovery to resting-state 
conditions after the passage of a nervous impulse. The distribution of these 
molecules along the axonal membrane is closely associated with the 
discontinuous segmental structure of the electrically insulating myelin 
sheath, and it is proposed that the latter participates actively in the 
establishment of this distribution (Waxman and Ritchie, 1993, Salzer, 1997). 
The myelin sheath, through its electrical resistance and low capacitance, 
allows the depolarization of the internodal axonal membrane with a 
minimal consumption of energy. Indeed, the highly concentrated sodium 
channels located at the nodes of Ranvier are activated by the 
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depolarisation of the axonal membrane induced by the arrival of a wave 
of positively charged sodium ions, thus allowing the massive influx of more 
sodium ions into the axon and causing a new wave of depolarisation. The 
latter, following the sodium concentration gradient, is passively transmitted 
along the insulated internodal segment of the axon, to the next node of 
Ranvier, where a new action potential is generated. Due to the segmental 
disposition of the electrically insulating myelin membrane, the action 
potential appears to jump from one node of Ranvier to the next: hence the 
term “saltatory conduction” (Ritchie, 1984). Exactly the same process is 
involved in the conduction along non-myelinated fibers, except that the 
sodium channels are distributed along the whole length of the axon. The 
smaller density of the channels leads to a smaller amplitude of the 
depolarisation wave, whose effective range is therefore shorter, leading in 
turn to a slower rate of transmission of the nervous impulse along the axon. 
The insulating role played by the myelin sheath is crucial for the correct and 
efficient functioning of the nervous system, as evidenced by the 
devastating effects of myelin loss from both the PNS, in genetic diseases 
such as the Guillain-Barrè syndrome and Charcot-Marie-Tooth disease or in 
autoimmune diseases such as Diabetes Mellitus, and the CNS, in diseases 
such as multiple sclerosis. Next we will focus our attention on organization 
and composition in myelin sheath of PNS tryng to underline the importance 
of this phisiological structure, and to point out the risk of its loss after the 
appearance of myelin abnormalities caused by diabetes mellitus (Veiga et 
al., 2006a).  
MYELIN SHEATH ORGANISATION IN THE PERIPHERAL NERVOUS 
SYSTEM 
In PNS, myelin is formed by the differentiation of the plasma membrane of 
Schwann cells. The latter, named after Schwann who first described them 
160 years ago, are flattened cells with an elongated nucleus orientated 
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longitudinally along the nerve fiber. The elaboration of the electrically 
insulating myelin sheath by the Schwann cells requires concentrating large 
amounts of non-conducting material around segments of the axon and 
excluding as much aqueous, cytosolic material from the structure as 
possible. At the same time, access to all levels of the sheath must be 
ensured in order to allow its maintenance, and regularly spaced, non-
insulated segments have to be left to allow the generation of the action 
potentials by the sodium channels of the axon. The solution found by the 
Schwann cell was to elaborate a highly lipid-rich plasma membrane with 
high contents of galactosphingolipids and saturated very long-chain fatty 
acids, and to wrap this membrane tightly around the axon many times 
(Mugnaini, 1982).  
PNS MYELIN COMPOSITION 
The myelin sheath is a morphologically complex entity composed of both 
non-compacted structures and a significantly large proportion of 
compacted membranes, each of which plays important roles in the 
integrated function of the sheath. This structural complexity presents a 
substantial problem for the biochemical characterization of myelin, till 
today the most common method to analyse the isolated myelin 
composition was described by Norton and Poduslo (Norton and Poduslo, 
1973) and allows the isolation of a fraction highly enriched in large 
fragments of the compacted membrane components of the sheath. 
Therefore, as underlined by Mugnaini over 20 years ago (Mugnaini, 1982) 
one should be aware that many of the properties relating to the 
biochemical composition of “myelin” presented in the literature, even 
recently, are representative of only one part of the myelin sheath, and 
should not be extrapolated to englobe the numerous other structures, 
about which we still know relatively little. Bearing this in mind, one of the 
major biochemical characteristics that distinguishes myelin from other 
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biological membranes is its high lipid-to-protein ratio: isolated myelin 
contains 70±80% lipids and 20±30% proteins. This relatively high lipid content 
and the particular characteristics of the lipids present in the sheath, provide 
the electrically insulating property required for the saltatory propagation of 
the nervous influx. 
 
LIPIDS 
Fatty Acids Biosynthesis 
In eukaryotes, fatty acid synthesis depends on a large soluble multienzyme 
complex that carries out the sequential enzymatic reactions required to 
build fatty acids. Structural determination of the fatty acid synthase has 
provided insights into how its multiple enzymatic activities work together to 
perform reiterative cycles of fatty acid synthesis (Leibundgut et al., 2007, 
Jenni et al., 2006). Fatty acid synthesis begins with the transfer of acetyl and 
malonyl groups from their CoA derivatives to a sulfhydryl group on the acyl 
carrier protein (ACP) domain of fatty acid synthase. An acetyl group from 
the malonyl-ACP is transferred to the acetyl-ACP to form an acetoacyl-
ACP, which is reduced, dehydrated, and reduced again to saturate the 
growing acyl chains inside a cavity of the fatty acid synthase complex. This 
process is repeated until the fatty acids reach a length of 16 carbons. The 
growing hydrophobic acyl chains remain soluble because they are bound 
to the ACP domain, which delivers the substrate to the four different 
enzymatic domains of the reaction cycle.  
 
Long-Chain Saturated Fatty Acids Are Synthesized from Palmitate 
Palmitate, the principal product of the fatty acid synthase system in animal 
cells, is the precursor of other long-chain fatty acids. It may be lengthened 
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to form stearate (18:0) or even longer saturated fatty acids by further 
additions of acetyl groups, through the action of fatty acid elongation 
systems present in the smooth endoplasmic reticulum and in mitochondria. 
The more active elongation system of the ER extends the 16-carbon chain 
of palmitoyl-CoA by two carbons, forming stearoyl-CoA. Although different 
enzyme systems are involved, and coenzyme A rather than ACP is the acyl 
carrier in the reaction, the mechanism of elongation in the ER is otherwise 
identical to that in palmitate synthesis: donation of two carbons by malonyl-
CoA, followed by reduction, dehydration, and reduction to the saturated 
18-carbon product, stearoyl-CoA. 
 
Desaturation of Fatty Acids Requires a Mixed-Function Oxidase 
Palmitate and stearate serve as precursors of the two most common 
monounsaturated fatty acids of animal tissues: palmitoleate, 16:1(Δ9), and 
oleate, 18:1(Δ9); both of these fatty acids have a single cis double bond 
between C-9 and C-10. The double bond is introduced into the fatty acid 
chain by an oxidative reaction catalyzed by fatty acyl–CoA desaturase, a 
mixed-function oxidase. Two different substrates, the fatty acid and NADH 
or NADPH, simultaneously undergo two-electron oxidations. The path of 
electron flow includes a cytochrome (cytochrome b5) and a flavoprotein 
(cytochrome b5 reductase), both of which, like fatty acyl–CoA desaturase, 
are in the smooth ER. Bacteria have two cytochrome b5 reductases, one 
NADH-dependent and the other NADPH-dependent; which of these is the 
main electron donor in vivo is unclear. In plants, oleate is produced by a 
stearoyl-ACP desaturase in the chloroplast stroma that uses reduced 
ferredoxin as the electron donor. Mammalian hepatocytes can readily 
introduce double bonds at the Δ9 position of fatty acids but cannot 
introduce additional double bonds between C-10 and the methyl-terminal 
 2. Introduction 
 
 
 19 
end. Thus mammals cannot synthesize linoleate, 18:2(Δ9,12), or α-linolenate, 
18:3(Δ9,12,15). Plants, however, can synthesize both; the desaturases that 
introduce double bonds at the Δ12 and Δ15 positions are located in the ER 
and the chloroplast. The ER enzymes act not on free fatty acids but on a 
phospholipid, phosphatidylcholine, that contains at least one oleate linked 
to the glycerol. Both plants and bacteria must synthesize polyunsaturated 
fatty acids to ensure membrane fluidity at reduced temperatures. Because 
they are necessary precursors for the synthesis of other products, linoleate 
and linolenate are essential fatty acids for mammals; they must be 
obtained from dietary plant material. Once ingested, linoleate may be 
converted to certain other polyunsaturated acids, particularly γ-linolenate, 
eicosatrienoate, and arachidonate (eicosatetraenoate), all of which can 
be made only from linoleate. Arachidonate, 20:4(Δ5,8,11,14), is an essential 
precursor of regulatory lipids, the eicosanoids. The 20-carbon fatty acids are 
synthesized from linoleate (and linolenate) by fatty acid elongation 
reactions. 
Fatty Acids Composition of Myelin Sheath 
All the major lipid classes (neutral lipids, phosphoglycerides and 
sphingolipids) and their respective subclasses encountered in other 
membranes, are also represented in the myelin membrane and thus, strictly 
speaking, there are no myelin-specific lipids. This absence of myelin-specific 
lipids contrasts sharply with the situation for the proteins, of which there are 
myelin-specific components. In both mammalian and non-mammalian 
species, lipids account for 72-78% of the dry mass of PNS myelin, and there 
appear to be significant differences between the relative quantitative 
distributions of the various major lipid subclasses from one species to 
another. In mice, the variability in the absolute amount of each polar 
lipid/cm of whole nerve from one individual to another seems to increase 
with age. However, the relative proportions of each lipid present in the 
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nerves of different mice at a given age is subject to less variation and, thus, 
seems to be more closely controlled (Heape et al., 1986). Cholesterol 
accounts for 20-30% of the total lipids in the PNS. In mouse and rabbit 
sciatic nerves, cholesterol accumulates continuously throughout the period 
of neo-myelinogenesis and during the subsequent period of myelin 
maturation (Yates and Wherrett, 1974, Juguelin et al., 1986). This 
accumulation pattern is consistent with the role proposed for this lipid in the 
stabilization and the compaction of the multilamellar myelin membrane 
(Nussbaum et al., 1969, Detering and Wells, 1976). There are more 
ethanolamine phosphoglycerides (28-39%) than those with choline, and 
plasmalogens (phosphatidalcholine and phosphatidalethanolamine) are 
reported to be significantly abundant in the PNS. Sphingomyelin is more 
enriched in peripheral nerve myelin, where it represents 10-35% of the total 
lipids, than in brain myelin, where it accounts for only 3-8% of the lipids 
(Norton and Cammer, 1984). Phosphatidylserine is not particularly 
abundant in the myelinated peripheral nerves of mice. Perhaps the most 
striking feature of the myelin lipid composition when compared to that of 
other biological membranes is the high content in 
monogalactosylsphingolipids, with cerebrosides (Gal-C) and sulfatides 
(SGal-C) accounting for 14-26% and 2-7%, respectively, of the total PNS 
myelin lipid mass in adults. These levels are nevertheless lower than those 
encountered in the CNS. PNS myelin also contains gangliosides 
(sphingolipids with an oligosaccharide head group including one or more 
sialic acid residues), but here again, the amounts are lower than those 
encountered in the CNS (Fong et al., 1976). The fatty acyl components of 
the myelin lipids present a distinctive distribution when compared with 
those observed in non-myelin membranes. Oleic acid [C18:1(n-9)] is the 
major fatty acid in the PNS myelin, comprising between 30 and 40% of the 
fatty acids of sciatic nerves (Pratt et al., 1969, Fressinaud et al., 1986, Bourre 
et al., 1993). The fatty acid composition appears to be similar in rats and 
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mice. For example, the proportions of C18:0, C18:1 and C18:2 measured in 
the 25-day-old mouse sciatic nerves are 9%, 33% and 3%, respectively 
(Garbay et al., 1998), while those in 21-day-old rat sciatic nerves are 6.5% 
for C18:0, 35% for C18:1 and 5% for C18:2 (Bourre et al., 1993, Bourre et al., 
1997). Besides the high levels of fatty aldehydes associated with the 
plasmalogens, most of which are palmitoyl (C16:0), stearoyl (C18:0) and 
oleoyl (C18:1) derivatives, myelin is also characterized by its relatively high 
content in very long-chain fatty acids (>18 carbon atoms). The fatty acid 
composition has been determined for individual lipids (Klein and Mandel, 
1978, Yao, 1982), for both the endoneurium and the perineurium of adult 
rats (Fressinaud et al., 1986), and for the whole mouse sciatic nerve during 
postnatal development (Heape et al., 1987). While the results of these 
studies are often difficult to compare due to differences in the approaches 
employed, taken together, they indicate that there is a high enrichment in 
saturated very long-chain fatty acids (20±24 carbon atoms) in myelinated 
peripheral nerve tissue, and that the large majority of these are present in 
the sphingolipids. The very long-chain fatty acids are mostly saturated and 
a-hydroxylated, or non-hydroxylated, and are amidified to the primary 
amine function of the lipid's sphingosyl moiety. The sphingosyl-fatty acyl 
couple comprises the ceramide “module” common to all sphingolipids and 
whose diversity is determined by the nature of the fatty acyl component. As 
in the CNS myelin, the most abundant of the very long-chain fatty acyl 
groups in adult mouse sciatic nerves is lignoceric acid (C24:0) (Heape et al., 
1987). 
PROTEINS 
Proteins in PNS myelin represent between 20 and 30% of the myelin dry 
mass. One of the characteristics of PNS myelin proteins is that at least 60% 
are glycoproteins (glycoproteins are minor constituents of CNS myelin). 
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GLYCOPROTEINS 
 After separation of rat PNS myelin proteins by sodium dodecylsulfate-
polyacrylamide gel electrophoresis, followed by nitrocellulose transfer and 
overlay with various radiolabeled lectins, Shuman (Shuman et al., 1983), 
detected 26 distinct glycoproteins. Only four glycoproteins appeared to be 
quite abundant. The most abundant is a 28 kDa protein, named protein-
zero, or P0 (Kitamura et al., 1976, Roomi et al., 1978). A 22 kDa glycoprotein, 
called PAS II, was purified and characterized by Kitamura (Kitamura et al., 
1976); this protein is now known as Peripheral Myelin Protein 22, or PMP22. 
Two high molecular mass glycoproteins are present in relatively small 
amounts: a 170-kDa protein (Shuman et al., 1983), now referred to as 
Periaxin, and the 100 kDa Myelin-Associated Glycoprotein, or MAG 
(Sternberger et al., 1979), which was first described in CNS myelin (Quarles 
et al., 1973). Epithelial cadherin (E-cadherin) was also recently shown to be 
present in small amounts in PNS myelin (Fannon et al., 1995). 
Protein zero (P0)  
P0 is the major protein of PNS myelin and represents between 50-70% of the 
total protein (Greenfield et al., 1973, Wiggins et al., 1975). It is a 28 kDa 
integral membrane glycoprotein, which, in mammals, appears to be 
expressed by myelinating Schwann cells, but neither by CNS glia, nor by the 
non-myelinating Schwann cells that populate many peripheral nerves 
(Brockes et al., 1980, Trapp et al., 1981, Martini and Schachner, 1988, Lemke 
and Chao, 1988). P0 protein is highly conserved among species (Sakamoto 
et al., 1987). The putative role for the P0 protein is to function as a 
membrane adhesion molecule and to promote and maintain the very tight 
compaction of the myelin structure by homophilic interactions ((Kirschner 
and Ganser, 1980, Lemke and Axel, 1985) X- ray data suggested that the 
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extracellular domain of P0 forms tetramers, with four molecules arranged 
around a central hole (Shapiro et al., 1996). These tetramers, also more 
recently observed with the full-length P0 protein (Inouye et al., 1999), may 
interact with their counterparts on the apposing cell membrane, holding 
the two extracellular surfaces together.  
Peripheral myelin protein 22 kDa (PMP22)  
Peripheral Myelin Protein 22, or PMP22, is a small, 22 kDa glycoprotein that 
was first purified and characterized from bovine PNS myelin (Kitamura et al., 
1976). It represents 2-5% of PNS myelin proteins (Pareek et al., 1993). The 
PMP22 mRNA was cloned by differential colony hybridization screening of 
cDNA libraries from regenerating rat sciatic nerve (De Leon et al., 1991, 
Spreyer et al., 1991, Welcher et al., 1991). Analysis of the corresponding 
cDNA clones revealed a mature protein of 18 kDa, containing four putative 
transmembrane domains (Manfioletti et al., 1990). This glycoprotein carries 
an N-linked glycosylation (at asparagine 41) in its first putative extracellular 
loop, which is consistent with the apparent molecular mass of 22 kDa of the 
PMP22 protein purified from sciatic nerves (Snipes et al., 1993). The 
carbohydrate residue may be involved in mediating adhesive processes 
(Snipes et al., 1993), suggesting that its function in myelin may be similar to 
that of the P0 glycoprotein (Pareek et al., 1993). The expression of PMP22 is 
not restricted to the PNS, since the corresponding mRNA has been 
detected, albeit in low quantities, in lung, gut, heart, brain and NIH3T3 
fibroblasts (Manfioletti et al., 1990, Spreyer et al., 1991, Welcher et al., 1991). 
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2.3 NEUROSTEROIDS 
SYNTHESIS, METABOLISM AND RECEPTORS OF NEUROACTIVE 
STEROIDS IN NERVOUS SYSTEM  
Several observations have demonstrated that Schwann cells and glial cells 
express Peripheral Benzodiazepine Receptor (PBR), now renamed as TSPO 
(Papadopoulos et al., 2006), its endogenous ligands are 
octadecaneuropeptide (Lacor et al., 1996, Lacor et al., 1999, Schumacher 
et al., 2001) and StAR (Benmessahel et al., 2004). These molecules 
participate in the cholesterol transport from intracellular stores to the inner 
mitochondrial membrane where the P450scc (i.e., the enzyme that 
converts cholesterol to pregnenolone, PREG) is located. Both P450scc and 
3β-HSD (i.e., the enzyme converting pregnenolone into progesterone, 
PROG) are present in Schwann cells (Mensah-Nyagan et al., 1999; Mellon et 
al., 2001). Moreover, metabolism of native steroids into their 5α- and 3α-
hydroxy-5α reduced derivatives via the enzymatic complex formed by the 
5α-Reductase (5α-R) and the 3α-HSD (Melcangi et al., 2004) also occurs in 
peripheral nerves and in central nervous system. In particular, PROG can be 
converted into Dihydroprogesterone (DHP) and subsequently into 
Tetrahydroprogesterone (3α,5α-THP) or into the isomer Isoallopregnanolone 
(3β,5α-THP), Testosterone (T) into Dihydrotestosterone (DHT) and then into 
5α-androstane-3α,17β-Diol (3α-Diol) or into isomer  5α-androstane-3α,17β-
Diol (3β-Diol) (Melcangi et al., 2001b). Estrogens (E) can be aromatized 
directly from T or can be synthesized from androstenedione passing to the 
intermediate estrone (Melcangi et al. 2008); the synthesis via peripheral 
nerves in Schwann cells and central nervous system in glial cells, not only 
synthesizes and metabolizes neuroactive steroids, but also expresses 
classical and non-classical steroid receptors. Namely, classical steroid 
receptors for PROG (PR), estrogens (ER), androgens (AR), glucocorticoids 
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and mineralocorticoids (Groyer et al., 2006) have been demonstrated in rat 
in Schwann cells and in brain (Melcangi et al. 2008). In particular, AR 
expression has been demonstrated in rat sciatic nerve, but it seems to be 
located in the endoneurial compartment and not in Schwann cells (Jordan 
et al., 2002; Magnaghi et al., 1999). In central nervous system, neuroactive 
steroids have been reported to modulate also neurotransmitter receptors, 
like for instance γ-Amino Butyric Acid type A and B (GABA-A and GABA-B 
receptors), serotonin type 3 (5-HT3), N-Methyl-D-Aspartate (NMDA), α-
Amino-3-hydroxy-5-Methyl-4-isoxazole Propionic Acid (AMPA), kainate 
receptor and an atypical intracellular receptor like the sigma 1 (Lambert et 
al., 2001, 2003; Maurice et al., 2001; Romieu et al., 2003). Some of these 
receptors, such as GABA-A (i.e., α2, α3, β1, β2 and β3 subunits) and GABA-B 
(i.e., GABA-B1 and GABA-B2) receptors have been identified (Melcangi et 
al., 1999; Magnaghi et al., 2004a) also in peripheral nerves and Schwann 
cells. Moreover, rat nerve expresses NMDA receptor 1 subunit, Glutamate 
Receptor 1 (GluR 1) AMPA subunit and GluR 5, 6 and 7 kainate subunits 
(Coggeshall and Carlton, 1998; Verkhratsky and Steinhauser, 2000), and 
Schwann cells of mammalian peripheral vestibular system express GluR 2, 3 
and 4 (Dememes et al., 1995; Verkhratsky and Steinhauser, 2000). Finally, 
the presence of sigma 1 receptor has been recently confirmed at the level 
of Schwann cells of rat sciatic nerve (Palacios et al., 2004). 
PERIPHERAL NERVOUS SYSTEM RESPONSES TO NEUROACTIVE 
STEROIDS 
It is now clear that neuroactive steroids are able to modulate the expression 
of myelin proteins of PNS, such as P0 and the Peripheral Myelin Protein 22 
(PMP22). Both in vivo (i.e., in the rat sciatic nerve) and in vitro (i.e., in 
cultures of rat Schwann cells), the synthesis of these two important myelin 
proteins is modulated by the treatment with PROG and its derivatives. 
Namely, the expression of P0 in sciatic nerve of adult male rats, as well as 
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that in rat Schwann cell culture, is increased by the treatment with PROG, 
5α-DHP or 3α,5α-THP, while in case of PMP22, only 3α,5α-THP is effective 
(Melcangi et al., 1998, 1999, 2001a,b, 2005). Not only PROG and its 
neuroactive derivatives are able to influence the synthesis of myelin 
proteins, but also neuroactive derivatives of T are effective. For instance, in 
adult male rats, castration decreases the expression of P0 in the sciatic 
nerve (Magnaghi et al., 1999, 2004b) and the subsequent treatment with 
DHT or 3α-Diol is able to restore the levels of the messenger of this myelin 
protein (Magnaghi et al., 1999, 2004b). Castration also decreases the mRNA 
levels of PMP22 in sciatic nerve, but in this case only 3α-Diol is able to 
counteract this effect (Magnaghi et al., 2004b). A very similar pattern of 
effects is also evident in cultures of rat Schwann cells. In this experimental 
model, DHT increases P0 mRNA levels (Magnaghi et al., 1999), while the 
treatment with 3α-Diol increases PMP22 mRNA levels (Melcangi et al., 
2000a). Several mechanisms seem to be involved in the effects of 
neuroactive steroids on the expression of myelin proteins. Thus, the 
expression of P0 seems to be under the control of classical receptors, such 
as PR and AR, while a role for a non-classical steroid receptor, like GABA-A 
receptor may be hypothesized in case of PMP22 (Melcangi et al., 2005). PR 
involvement on the expression of P0 may be confirmed by the finding that 
in cultured rat Schwann cells an antagonist of this steroid receptor, such as 
mifepristone, is able to block the stimulatory effect exerted by PROG or DHP 
(i.e., classical ligands of PR). Interestingly, this antagonist is also effective in 
blocking the effect of 3α,5α-THP (i.e., a neuroactive steroid which is able to 
interact with GABA-A receptor) on P0 (Magnaghi et al., 2001). Indeed, the 
activity of the 3α-HSD is bi-directional (Melcangi et al., 2001b) and 
consequently 3α,5α-THP might be retroconverted into DHP exerting its effect 
on P0 via an activation of PR. A role for the classical PR is also supported by 
in vivo observations. For instance, treatment with mifepristone since the first 
day of life decreases 20 days later the expression of P0 (Melcangi et al., 
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2003a). Activation of a classical steroid receptor, such as PR, clearly 
suggests that the effect of PROG derivatives on P0 expression is due to a 
classical steroid genomic effect. This hypothesis is supported by the finding 
that a coactivator, such as Steroid Receptor Coactivator-1 (SRC-1) 
participates in the regulation of P0 gene expression by DHP. Indeed, as 
demonstrated in an immortalized cell line of Schwann cell (i.e., MSC80 cells) 
stably transfected to over- or down-express SRC-1, the effect of DHP on P0 
expression was increased or completely lost respectively (Cavarretta et al., 
2004). Moreover, a further support to the hypothesis that P0 is under the 
control of a classical steroid genomic mechanism is that putative 
progesterone responsive elements are present on P0 gene (Magnaghi et 
al., 1999). A role for AR in controlling expression of P0 may be also 
hypothesized. Indeed, in vivo treatment with an antagonist of this steroid 
receptor (i.e., flutamide) decreases the synthesis of P0 in rat sciatic nerve 
(Magnaghi et al., 2004b). Interestingly, inhibition of AR influences P0 
synthesis in adult age only. This age-linked effect is different from what we 
have observed after the in vivo treatment with mifepristone, where PR 
antagonist is only able to decrease the synthesis of P0 at postnatal day 20 
(Melcangi et al., 2003a). A possible hypothesis could be that PROG 
derivatives may be necessary for inducing P0 synthesis during the first steps 
of the myelination process, while the subsequent intervention of T 
derivatives will participate in the maintenance of this process. As 
mentioned above, the expression of PMP22 seems to be under the control 
of GABA-A receptor. In fact, experiments performed in Schwann cell 
cultures utilizing agonists or antagonists of GABA-A receptor have indicated 
that bicuculline (i.e., a specific antagonist of this receptor) completely 
abolishes the stimulatory effect exerted by 3α,5α-THP on PMP22, while 
muscimol (i.e., an agonist of GABA-A receptor) exerts a stimulatory effect 
on PMP22, which is comparable to that exerted by 3α,5α-THP (Magnaghi et 
al., 2001). The specificity of the effect of 3α,5α-THP on the GABA-A receptor 
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is also supported by the finding that isopregnanolone, which does not 
interact with GABA-A receptor, is unable to modify the expression of this 
myelin protein. Moreover, the finding that among T derivatives so far 
considered, only 3α-Diol (i.e., a neuroactive steroid which is able to interact 
with GABA-A receptor) significantly increases PMP22 mRNA levels 
(Magnaghi et al., 2004b; Melcangi et al., 2000a) gives further support to the 
role of GABA-A receptor in controlling PMP22 expression. Recent data, 
however, indicate that P0 and PMP22 expression is not only merely under 
the control of classical (i.e., PR and AR) and non-classical steroid (GABA-A 
receptor) receptors respectively, but sex is another variable. As recently 
demonstrated, at least in culture of rat Schwann cells, the effects of PROG 
and its derivatives on the expression of myelin proteins are sexually 
dimorphic (Magnaghi et al., 2006). Interestingly, neuroactive steroids not 
only regulate the expression of myelin proteins but also that of transcription 
factors (TFs) with a key role in Schwann cell physiology and in their 
myelinating program. For instance, data obtained in culture of rat Schwann 
cells (Guennoun et al., 2001; Mercier et al., 2001) have indicated that PROG 
stimulates the gene expression of Krox-20, Krox-24, Egr-3 and FosB. 
Moreover, we have recently demonstrated that not only PROG, but also its 
derivatives affect the synthesis of TFs, such as Krox-20 and Sox-10. Indeed, in 
culture of rat Schwann cells the expression of Krox-20 is stimulated by the 
treatment with DHP or 3α,5α-THP, while that of Sox-10 is only stimulated by 
DHP (Magnaghi et al., 2007). These observations, together with the concept 
that PROG derivatives are also able to influence directly the expression of 
myelin proteins suggest that they might coordinate Schwann cell 
myelinating program utilizing different intracellular pathways. Neuroactive 
steroids not only influence the expression of myelin proteins by Schwann 
cells but they also affect their proliferation. A stimulatory effect of PROG on 
proliferation of Schwann cells has been detected in vitro (Svenningsen and 
Kanje, 1999; Bartolami et al., 2003). An effect of androgens on Schwann cell 
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proliferation is also evident. Namely, the number of terminal Schwann cells 
unsheathing the synaptic junction between motor nerve endings and 
muscles decreases after castration and this effect is counteracted by T 
replacement (Lubischer and Bebinger, 1999). In addition, not only 
neuroactive steroids themselves, but also steroid coactivators, which, as 
previously mentioned participate in the effects exerted by neuroactive 
steroids on myelin proteins, are able to affect cell proliferation. It has been 
demonstrated that cell proliferation in immortalized Schwann cell lines (i.e., 
MSC80 cells) overexpressing SRC-1 is slower than in cells in which the 
coactivator expression is down regulated (Melcangi et al., 2005). In 
contrast, overexpression of another coactivator, such as Steroid Receptor 
RNA Activator (SRA), induces an increase in the proliferation of MSC80 cells 
(Melcangi et al., 2005). 
The effects of neuroactive steroids mentioned above on the expression of 
myelin proteins and Schwann cell proliferation have important 
repercussions for myelin formation and the maintenance of myelin 
structure. Effects of neuroactive steroids on the expression of myelin proteins 
such as P0 and PMP22 are particularly relevant since these two proteins 
play an important role for the maintenance of the multilamellar structure of 
PNS myelin (D'Urso et al., 1990). P0, a member of the immunoglobulin gene 
superfamily (IgCAM), accounts for more than half of the total peripheral 
myelin proteins (Ishaque et al., 1980), and it is predominantly confined to 
the compact portion of the mature myelin. The importance of P0 for 
stabilizing compact myelin is illustrated by the severe phenotype of P0-
negative mice generated by homologous recombination (Giese et al., 
1992; Martini et al., 1995; Zielasek et al., 1996), with pathological alterations 
affecting both myelin and axonal compartments, similar to those occurring 
in some dominantly inherited human peripheral neuropathies (e.g., 
Charcot-Marie-Tooth type 1b, CMT1B and Déjérine-Sottas syndrome, DSS). 
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In agreement with the effect exerted on the proteins of peripheral myelin, 
PROG is also able to stimulate the myelin synthesis itself. For instance, PROG 
is able to accelerate the time of initiation and to enhance the rate of 
myelin synthesis in Schwann cells co-cultured with Dorsal Root Ganglia 
(DRG) neurons (Chan et al., 1998, 2000). Moreover, recent observations 
have indicated that also axonal compartment of PNS neurons may be 
considered a target for the action of neuroactive steroids. Thus, PROG 
affects the expression of neuronal genes that may promote myelination 
process by Schwann cells. For instance, in co-culture of Schwann cells and 
DRG neurons two genes, like a small Ras-like GTP binding protein (Rap 1b) 
and phosphoribosyl diphosphate synthase-associated protein, which are 
induced in co-cultures during myelin synthesis, are also induced by PROG 
treatment (Chan et al., 2000; Rodriguez-Waitkus et al., 2003). Moreover, it 
has been observed that the blockade of PR results in axonal impairment in 
the sciatic nerve of male rats. Indeed, morphological analysis of sciatic 
nerves of animals treated with mifepristone during development indicates a 
reduced axon diameter compared to myelin thickness and an increased 
neurofilament density (Melcangi et al., 2003a). 
Neuroactive steroids act in peripheral nerves as physiological regulators 
and as protective agents for acquired and inherited peripheral neuropathy 
(Melcangi and Garcia- Segura, 2006; Schumacher et al., 2007; Roglio et al., 
2008b; Melcangi and Panzica, 2009). Previous studies have shown that the 
levels of neuroactive steroids are reduced in the peripheral nerves of STZ 
diabetic rats (Caruso et al., 2008; Pesaresi et al., 2010). In turn, the 
administration of neuroactive steroids improves the neuropathic phenotype 
induced by diabetes (Veiga et al., 2006; Leonelli et al., 2007; Roglio et al., 
2007; Cermenati et al., 2010). This suggests that increasing the levels of 
neuroactive steroids directly in the nervous system could be a therapeutic 
approach that may avoid the potential endocrine side effects of systemic 
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administration of neuroactive steroids. Indeed, we recently reported that a 
ligand of TSPO (Ro5-4864) that increases the local concentration of 
neuroactive steroids is effective at reducing the severity of diabetic 
neuropathy (Giatti et al., 2009). 
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2.4 LIVER X RECEPTORS 
Steroidogenesis occurs in peripheral nervous system (Garcia-Segura and 
Melcangi, 2006), and this nervous fibers express proteins involved in the 
initiation of steroidogenesis such as StAR and TSPO as well as the enzymes 
involved in the synthesis and metabolism of neuroactive steroids (Garcia-
Segura and Melcangi, 2006, Melcangi et al., 2008). Recently it was reported 
that StAR can also be modulate in the adrenal gland directly by Liver X 
Receptors (LXRs) (Cummins and Mangelsdorf, 2006). 
LXRs are members of the nuclear receptors superfamily. LXRs have the 
classical structure of a nuclear receptor: a DNA binding domain, a ligand 
binding domain and a ligand independent activation function 2 (AF2) that, 
through the recruitment of coactivators and corepressors, regulates the 
activity of the receptor. 
More than ten years ago these proteins were discovered, cloned and 
termed “orphan nuclear receptors” (Chawla et al., 2001). Today, since the 
physiological ligands are known, they are classified as “adopted orphans”. 
Two different isoforms, LXRα (NR1H3) and LXRβ (NR1H2) are known. LXRα is 
predominantly expressed in the liver and at lower levels also in the intestine, 
macrophages, adipose tissue, lungs, kidneys and the adrenal gland, while 
LXRβ is broadly expressed (Li and Glass, 2004) including neurons, microglia, 
astrocytes (Gilardi et al., 2009) oligodendrocytes (Nelissen et al., 2012), and 
Schwann cells (Makoukji et al., 2011). 
LXRs are ligand activated transcription factors that form an obligate 
heterodimers with the Retinoic X Receptor (RXR). The LXR/RXR complex, 
activated by ligands, binds a specific sequence, called LXR Responsive 
Element (LXRE) in the promoter of the target genes modulating their 
expressions. Usually the DNA sequence recognized by LXRs is a direct 
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repeat of the core G/AGGTCA separated by four nucleotides DR-4 (Willy et 
al., 1995). However, it has been reported that LXR can also bind an inverted 
repeat (IR) sequence without spacing nucleotides (IR0) (Uppal et al., 2007). 
LXRs natural ligands are represented by oxysterols, an oxidized form of 
cholesterol produced from the cells as intermediates in steroid hormones or 
bile acids biosynthesis (Janowski et al., 1996). Accordingly with the nature of 
the physiological ligands, LXRs play an important role in cholesterol, and 
lipid metabolism. 
The role of LXRs as an intracellular cholesterol sensor is primarily due to the 
activation of key genes in cholesterol efflux such as the ATP Binding 
Cassette (ABC) family and in particular ABCA1, ABCG1, ABCG5 and 
ABCG8, Apolipoprotein E (ApoE) and Cholesterol Ester Transfer Protein 
(CETP) (Cummins and Mangelsdorf, 2006). This activation, mediated by high 
affinity ligands, increases HDL level and induces cholesterol efflux (Beaven 
and Tontonoz, 2006). LXRs also play a role in lipogenesis and triglyceride 
synthesis primarily due to the upregulation of Sterol Regulatory Element 
Binding Protein-1c (SREBP-1c) and Fatty Acid Synthase (FAS) (Repa et al., 
2000). All these genes are regulated by LXRs in a direct fashion due to the 
presence of one or multiple LXRE in the promoter region of the target 
genes. 
The literature on LXRs during the last two decades is mainly focused on the 
role of these nuclear receptors in the liver, adipose tissue, pancreas and 
skeletal muscle. During the last ten years several evidences have addressed 
the fundamental role of LXRs also in the nervous systems.  
LXR IN OBESITY AND DIABETES 
With the advent of genome-wide association studies, several groups have 
reported potential connections between human LXR genes and obesity 
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and diabetes. To date, however, the data are somewhat conflicting, and 
mechanistic links between specific genetic changes and human 
physiology remain to be established. As key metabolic tissues express both 
LXRα and LXRβ and the vast majority of the known LXR target genes 
respond to both receptors, it seems unlikely that even a complete loss of 
function in only one of the four LXR alleles would cause a dramatic 
phenotype. A recent study in individuals with type 2 diabetes identified a 
Single Nucleotide Polymorphism (SNP) in LXRβ, with the minor allele being 
associated with reduced pancreatic β-cell function. As pancreatic β-cells 
express LXRβ but not LXRα, it is understandable how an LXRβ polymorphism 
might have a functional effect in this cell type (Ketterer et al., 2011). Some 
studies have suggested that SNPs in both LXRα and LXRβ are linked to 
obesity phenotypes (Solaas et al., 2010), but others have not observed 
these associations (Auboeuf et al., 1997). In murine models of obesity and 
diabetes, pharmacologic LXR activation has both beneficial and 
detrimental effects on pathways related to glucose metabolism and insulin 
sensitivity. It has been demonstrated that 1 week of treatment with the LXR 
agonist GW3965 was associated with a substantial improvement in glucose 
tolerance in mice fed a high-fat diet (Laffitte et al., 2003). These effects 
were correlated with reduced hepatic glucose output and enhanced 
glucose uptake in adipose tissue (Laffitte et al., 2003). Similar effects were 
observed in leptin-deficient ob/ob mice, with no change in hepatic 
glucose output but increased Glucose Transporter Type 4 (GLUT4) 
expression in fat (Grefhorst et al., 2005). GW3965 administration to rats on a 
high-fat diet improved insulin suppression of free fatty acids, increased 
glucose infusion rate and reduced insulin suppression of glucose 
production; however, glucose uptake was not affected in this model 
(Commerford et al., 2007). Thus, short-term treatment with an LXR agonist 
seems to increase peripheral glucose disposal and improve glycemic 
control despite hepatic steatosis. Studies in adipose tissue have shown that 
 2. Introduction 
 
 
 35 
LXR protects against Tumour Necrosis Factor-α (TNFα)-induced insulin 
resistance, improving insulin signalling at the level of Insulin Receptor 
Substrate 1 (IRS1) in human adipocytes (Fernández-Veledo et al., 2009). 
Similar effects were observed in mouse primary brown adipocytes and were 
associated with improved translocation of GLUT4 to the plasma membrane 
(Joseph et al., 2004). Longer-term studies with LXR agonists and LXR-
deficient mice will be required to more precisely define the tissue-specific 
contributions of LXR signalling to lipid and glucose homeostasis.  
LXRS AS MASTER REGULATORS OF FAT METABOLISM 
In addition to their roles in cholesterol metabolism, the LXRs have profound 
effects on hepatic fat metabolism. These effects are mediated in part 
through the transcriptional regulation of SREBP-1c, the master regulator of 
fatty acid and triglyceride synthesis (Horton et al., 2002, Repa et al., 2000). 
LXRs bind two functional LXREs in the promoter region of the SREBP-1c gene, 
which are required for both the basal and inducible expression of SREBP-1c 
protein (Repa et al., 2000, Yoshikawa et al., 2001). In wild-type mice, 
cholesterol feeding or administration of a synthetic ligand for LXR and its 
heterodimeric partner RXR resulted in increased SREBP-1c expression, 
nuclear SREBP-1c protein levels, and fatty acid synthesis. These effects were 
abrogated in LXR-null mice, which are refractory to both cholesterol- and 
insulin-induced expression of SREBP-1c (Repa et al., 2000). In addition to 
SREBP-1c, other lipogenic genes, such as fatty acid synthase (FAS), have 
been reported as direct LXR targets (Joseph et al., 2002). In addition to the 
regulation of lipogenic gene expression, LXRs are involved in the regulation 
of fat metabolism, particularly as it relates to the diet. For example, a wild-
type mouse requires LXRs to process and store dietary fat properly (Kalaany 
et al., 2005). When fed a high-fat, high-cholesterol “Western”-style diet, LXR-
null mice are resistant to obesity and show better glucose tolerance. LXR-
null mice, in fact, did not store dietary fat but they burn it off in their 
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peripheral tissues and display significantly increased metabolic rates and 
markedly suppressed hepatic fatty acid synthesis. Interestingly, resistance to 
diet-induced obesity depends on the presence of dietary cholesterol; this 
finding underlined an essential role for LXRs in regulating the balance 
between fat storage and oxidation (Kalaany et al., 2005). This study and 
others revealed the existence of an SREBP-1c-independent regulatory 
pathway to regulate hepatic fat metabolism and showed that LXRs are 
required for both the basal (Peet et al., 1998, Repa et al., 2000) and insulin-
induced expression of SREBP-1c (Chen et al., 2004). From a 
pharmacological point of view, the finding that LXR agonists can regulate 
fat metabolism has been a thorn in the development of drugs such as those 
for reducing body cholesterol levels, enhancing insulin sensitivity, and 
protecting against atherosclerosis. Indeed, oral administration of the potent 
synthetic agonist T0901317 in mice and hamsters leads to increased hepatic 
fatty acid synthesis, hepatic steatosis, and increased VLDL triglycerides 
(Schultz et al., 2000, Grefhorst et al., 2002). When administered to 
hypercholesterolemic ApoE−/− or LDL receptor−/− mice, the LXR ligand also 
causes a 12-fold increase in plasma triglycerides (Grefhorst et al., 2002). 
Importantly, a majority of these detrimental lipid responses are due to 
activation of the SREBP-1c pathway (Kalaany et al., 2005, Liang et al., 2002), 
whereas activation of ABC transporters results in the beneficial therapeutic 
effects of lowering cholesterol. Interestingly SREBP-1c and the ABCA1 genes 
exhibit a striking difference in the ways in which LXRs regulate their 
promoters (Wagner et al., 2003): the absence of LXRs in mice causes 
derepression of basal ABCA1 expression in macrophages and the intestine; 
by contrast, basal SREBP-1c levels are decreased significantly. This is 
thought to result from the LXR-dependent, differential recruitment of the 
corepressors NCoR and SMRT to the ABCA1 and SREBP-1c promoters. 
Therefore, the development of an LXR partial agonist able to enhance 
basal expression of ABCA1 without affecting SREBP-1c expression would 
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have potential therapeutic value. The rationale for such pharmacological 
agents has been established with other nuclear receptor targets, such as 
the estrogen receptor (Osborne et al., 2000). From a physiological point of 
view, LXRs appear to function as upsteam master regulators of SREBP-1c-
dependent and -independent lipogenic pathways that are induced in 
response to increased sterol as well as insulin levels. Hence, the 
physiological function of LXRs points to a survival response by the body to 
efficiently store carbohydrate- and high-fat diet–derived energy in the form 
of body fat. 
LXRS AND CHOLESTEROL METABOLISM IN PERIPHERAL NERVOUS 
SYSTEM 
Peripheral neuropathies are common disorders affecting PNS. Peripheral 
neuropathies may arise during the aging process, after mechanical injury, 
by metabolic disorders (e.g., diabetes mellitus), by infections and 
autoimmune diseases, or after exposure to such type of therapeutics or 
toxic compounds. Damages to the PNS can also be inherited as in the case 
of the Charcot–Marie–Tooth (CMT) disease (Melcangi and Panzica, 2006). 
In the PNS also cholesterol plays a crucial role. In the PNS the majority of 
cholesterol is found in myelin and in particular in peripheral myelin 
producing cells such as the Schwann cells. To investigate the role of 
cholesterol in Schwann cells, two different mouse models have been 
generated and characterized. The first is a mouse model where the 
Squalene Synthase, a key enzyme to produce cholesterol, has been 
inactivated (SQS mice). The second model is a Schwann cells specific 
knock-out of the SREBP Cleavage Activation Protein (SCAP). Both models 
developed peripheral neuropathy due to a reduced myelination of the 
sciatic nerve. Moreover, in the SQS mutant Schwann cells it has been 
demonstrated that the export from the endoplasmic reticulum of the major 
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myelin protein P0 to growing myelin is dependent on cholesterol. These 
data undoubtedly prove the important role of cholesterol and fatty acids in 
myelin generation (Saher et al., 2005, Verheijen et al., 2009). Given the key 
role of lipids in the PNS and that LXRs are central in the regulation of 
cholesterol homeostasis and fatty acid metabolism, it is important to 
address their biology in this tissue either in physiological or in pathological 
conditions. Makoukji and colleagues highlighted the importance of LXRs in 
regulating myelin peripheral nerves. Indeed, this team demonstrated that 
LXRDKO mice displayed thinner myelin compared with the age matched in 
wild type control animals (Makoukji et al., 2011). Thus, the lack of LXRs in the 
sciatic nerve alters the myelin structure (Makoukji et al., 2011). 
Recently, it was reported that LXRs directly modulate Steroidogenic Acute 
Regulatory Protein (StAR) expression in the adrenal gland, a transfer protein 
regulating cholesterol shuttling into mitochondria, a key step in the initiation 
of steroid hormone synthesis (Cummins and Mangelsdorf, 2006). 
Steroidogenesis also occurs in peripheral nerves where it results in the 
formation of neuroactive steroids (Garcia-Segura and Melcangi, 2006, 
Melcangi et al., 2008). Peripheral nerves express proteins involved in the 
initiation of steroidogenesis, such as StAR and the Translocator Protein-18 
kDa (TSPO), as well as the enzymes involved in the synthesis and 
metabolism of neuroactive steroids, such as Cytochrome P450 side chain 
cleavage (P450scc), 3-Hydroxysteroid Dehydrogenase (3-HSD), and 5-
Reductase (5-R) (Garcia-Segura and Melcangi, 2006, Melcangi et al., 2008). 
Neuroactive steroids act in peripheral nerves as physiological regulators 
and as protective agents for acquired and inherited peripheral neuropathy 
(Garcia-Segura and Melcangi, 2006, Melcangi and Panzica, 2009). This 
suggests that increasing the levels of neuroactive steroids directly in the 
nervous system could be a therapeutic approach that may avoid the 
potential endocrine side effects of systemic administration of neuroactive 
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steroids. Indeed, we recently reported that a ligand of TSPO (Ro5-4864) that 
increases the local concentration of neuroactive steroids is effective at 
reducing the severity of diabetic neuropathy (Giatti et al., 2009). 
Given that neuroactive steroids are cholesterol-derived molecules, we 
hypothesized that LXRs may have protective effects on peripheral 
neuropathy by modulating the levels of these hormones. Supporting our 
hypotesis are some results obtained previously in a study by using a 
synthetic activator of the TSPO (Giatti et al., 2009).  
Moreover, Verheijen and colleagues, by using the SCAP Schwann cells-
specific knock-out demonstrated that not only cholesterol is important for 
myelin formation but also fatty acids (Verheijen et al., 2009). In fact, the 
LXRs directly regulate expression of the lipogenic transcription factor SREBP-
1c, and of key enzymes involved in FA biosynthesis, such as FAS and 
stearoyl-CoA desaturase-1 (SCD-1) (Kalaany and Mangelsdorf, 2006, Schultz 
et al., 2000). By the ability of LXRs to modulate lipid levels, an evaluation of 
the potential of a synthetic LXR activator to reverse diabetes-induced lipid 
abnormalities in sciatic nerve myelin could be hypotized.  
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Diabetic peripheral neuropathy (DPN) appears frequently in patients 
diagnosed with type 1 or type 2 diabetes (Association, 2007), this side effect 
is associated with deleterious changes in peripheral nerves, such as myelin 
damage and decrease in nerve conduction velocity (Sugimoto et al., 2000, 
Valls-Canals et al., 2002). The myelin sheath is a multilayered membrane 
produced in the peripheral nervous system by differentiation of the 
plasmatic membrane of Schwann cells (Garbay et al., 2000). The main role 
of this membrane is to allow efficient transmission of nerve impulses along 
the axons that it surrounds (Waxman and Ritchie, 1993). Several studies 
demonstrated that in the peripheral nerves of streptozotocin (STZ)-treated 
rats, an experimental model that captures many features of type 1 
diabetes (Herman, 2007) are present structural abnormalities and 
neurophysiological changes affecting this protective and functional 
structure (Veiga et al., 2006a).  
It is of interest to note that a role of neuroactive steroids as protective 
agents has been proposed for neurodegenerative diseases (Leonelli et al., 
2007).  
Neuroactive steroids have been shown to exert neuroprotective effects on 
central nervous system (CNS) and peripheral nervous system (PNS) in 
experimental models of diabetic neuropathy (Giatti et al., 2009, Pesaresi et 
al., 2010). It has been observed that nervous system is able to synthesise 
neuroactive steroids, and also to express different receptors that can bind 
neuroactive steroids achieving to exert protective effects. However, 
increasing the levels of neuroactive steroids directly in the nervous system 
could be a therapeutic approach that may avoid the potential endocrine 
side effects of systemic administration of neuroactive steroids. 
Recently, it was reported that Liver X Receptors directly modulate 
steroidogenic acute regulatory protein (StAR) expression in the adrenal 
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gland, a transfer protein regulating cholesterol shuttling into mitochondria, 
a key step in the initiation of steroid hormone synthesis (Cummins and 
Mangelsdorf, 2006).  
LXRs α and β (NR1H3 and NR1H2 respectively) are ligand activated 
transcription factors that belong to the nuclear receptor superfamily and 
they, upon activation, principally act preventing excessive cholesterol 
intracellular accumulation.  
In addition to their role in the regulation of cholesterol homeostasis, the LXRs 
also modulate fatty acid metabolism. In fact, the LXRs directly regulate 
expression of the lipogenic transcription factor SREBP-1c, and of key 
enzymes involved in fatty acid biosynthesis such as fatty acid synthase (FAS) 
and stearoyl-CoA desaturase-1 (SCD-1) (Schultz et al., 2000). Recently, it has 
been reported that in BB/Wor diabetic rats, type 1 diabetes reduces the 
expression of the lipogenic transcription factor SREBP-1c in Schwann cells 
(de Preux et al., 2007). It has also been shown that the acute phase of 
myelin lipid synthesis is regulated by SREBP cleavage activation protein 
(SCAP), an activator of SREBPs (Verheijen et al., 2009). These observations 
suggest that lack of insulin and/or of transcriptionally active SREBP-1c in 
peripheral nerves leads to decreased lipogenesis. Diminished or abnormal 
fatty acid synthesis may play an important role on altered myelin lipid and 
protein composition. Such changes in myelin could affect membrane 
fluidity and function, ultimately contributing to the pathogenesis of DPN 
(Verheijen et al., 2009). In support of this notion, studies in animal models 
have revealed a protective effect of administration of fatty acids on DPN 
(Coste et al., 2004). However, the specific changes in myelin lipid and 
protein composition induced by diabetes, as well as the molecular 
mechanism responsible for these defects, remain to be identified. 
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In this panorama, the aim of our research was to understand the role of LXR 
activation on peripheral neuropathy induced by diabetes. 
Our first objective is to understand whether LXR activation, due to is effect 
on StAR, drives neuroactive steroid synthesis in sciatic nerve, and if 
treatment with LXR ligands ameliorates diabetes induced neuropathy, as 
evaluated by a variety of functional and biochemical parameters. We try 
to demonstrate if LXR activation promotes steroidogenesis, cholesterol 
disposal, and raises the local levels of neuroactive steroids. An increase of 
these levels can exert neuroprotective effects against peripheral 
neuropathy induced by diabetes.  
Then we will focus our experiments on the LXRs ability to modulate fatty 
acids metabolism. The ability of LXRs to modulate lipid levels suggests the 
evaluation of LXR activation by a synthetic to reverse diabetes-induced 
lipid abnormalities in sciatic nerve myelin. Here, we would understand if LXR 
activation, by its ability to modulate fatty acids biosynthesis, is able to 
normalize myelin’s lipid profile, restores expression of genes involved in Fatty 
Acids (FA) biosynthesis, reestablishes nuclear levels of SREBP-1c and 
absolute levels of P0, and corrects the major myelin abnormalities induced 
by diabetes in peripheral nerves.  
At last we will investigate the possible crosstalk between these two different 
neuroprotective mechanisms involving steroids and fatty acids. In particular 
we will focus our attention on the neuroactive steroids that will be restored 
by LXR activation in diabetic setting as describe in the first objective. Once 
established which neuroactive steroids are brought-back to control levels 
we will administrate these molecules to diabetic animals to prove their role 
in regulating myelin structure, function and lipid composition. 
The analyses necessary to achieve these three objectives will be 
conducted on sciatic nerves or purified myelin of rats, using different 
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analytical techniques. Lipidomic profile analyses will use liquid 
chromatography tandem mass spectrometry (LC-MS/MS) and gas 
chromatography mass spectrometry (GC-MS). The lipidomic profile will be 
corroborated by gene expression analysis of key genes in fatty acid 
biosynthesis and will be complemented by a morphometric analysis of 
myelinated fibers. 
These studies will be carry out trying to extend the neuroprotective actions 
of LXR so far observed in multiple neuronal injury models, such as ischemic 
brain injury, Alzheimer’s disease, and Niemann-Pick C disease (Repa et al., 
2007, Zelcer et al., 2007, Morales et al., 2008, Sironi et al., 2008, Cheng et al., 
2010). Finally, we are trying to suggest that LXR may be a promising 
therapeutic target for diabetic neuropathy. 
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4.1 MATERIALS AND METHODS 
  
ANIMALS 
Two-month-old male Sprague Dawley rats, Crl:CD BR (Charles River) were 
used. The animals were maintained in quarters with controlled temperature 
and humidity. The light schedule was 14 h light and 10 h dark (lights on at 
6:30 AM). The animals were handled following the European Union 
Normative (Council Directive 86/609/EEC), with the approval of the 
Institutional Animal Use and Care Committees. Special care was taken to 
minimize animal suffering and to reduce the number of animals used to the 
minimum required for statistical accuracy. Induction of diabetes and 
experimental treatments. Diabetes was induced by a single i.p. injection of 
freshly prepared streptozotocin (65 mg/kg; Sigma) in 0.09 M citrate buffer, 
pH 4.8. Control animals were injected with 0.09 M citrate buffer at pH 4.8. 
Hyperglycemia was confirmed 48 h after streptozotocin injection by 
measuring tail vein blood glucose levels using a glucometer OneTouch 
Ultra2 (LifeScan). Only animals with plasma glucose levels >300 mg/ml were 
classified as diabetic. Glycemia was also assessed before and at the end of 
treatment with GW3965 (2 months after streptozotocin injection, see 
below), 3 months after streptozotocin administration. At 2 months, diabetic 
animals were treated once a week with GW3965 50 mg/kg (i.e., they 
received 4 subcutaneous injections) (STZ+GW3965 group) or every other 
day and for a month with a subcutaneous injection of DHP (STZ+DHP group) 
or 3α-diol (STZ+3α-diol group) (3.3 mg/kg body weight; total of sixteen 
treatments). The rationale for the once a week treatment with GW3965 is 
that daily systemic activation of LXRs is thought to result in 
hypertriglyceridemia (due to increased hepatic lipogenesis), an 
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undesirable side effect (Schultz et al., 2000). Thus, we sought to use the 
minimal dose of GW3965 that would show benefit while minimizing the 
potential for side effects. Nondiabetic and diabetic control rats were 
treated with vehicle. GW3965 was synthesized as previously described 
(Marino Jr et al., 2009). Non-diabetic and diabetic control rats were treated 
with vehicle (sesame oil). Special care was taken to minimize animal 
suffering and to reduce the number of animals used to the minimum 
required for statistical accuracy. 
REAGENTS 
Steroids analyses: 5-Pregnen-3β-ol-20-one (PREG), progesterone (PROG), 5α- 
pregnane-3, 20-dione (DHP), 3α-hydroxy-5α-pregnen-20-one (THP), 3β-
hydroxy-5α-pregnen-20-one (isopregnanolone), testosterone (T), 5α-
androstane-17β-ol-3-one (DHT), 5α-androstane-3α,17β-diol (3α- diol), and 
dehydroepiandrosterone (DHEA) were purchased from Sigma-Aldrich. 
2,2,4,6,6 –17α,21,21,21-D9-PROG (D9-PROG) was purchased from Medical 
Isotopes; 2,4,16,16-D4-17β-estradiol (D4- 17β-E) was obtained from CDN 
Isotopes. 17,21,21,21-D4-PREG (D4- PREG) was kindly synthesized by Prof. P. 
Ferraboschi (Department of Medical Chemistry, Biochemistry and 
Biotechnology, Universitá di Milano, Milano, Italy). Solid phase extraction 
(SPE) cartridges (Discovery DS-C18 500 mg) were from Supelco. All solvents 
and reagents were HPLC grade (Sigma-Aldrich). GW3965 was synthesized in 
house as previously described (Marino Jr et al., 2009). 
Fatty acids analyses: The internal standards (ISs) heneicosanoic acid (C21:0) 
and 5α-cholestane, and all other standards for FAs and cholesterol analyses 
were purchased from Sigma-Aldrich. 
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ASSESSMENT OF NEUROACTIVE STEROIDS BY LIQUID 
CHROMATOGRAPHY TANDEM MASS SPECTROMETRY 
Tissue and plasma samples were extracted and purified according to 
Caruso (Caruso et al., 2008). Briefly, samples (100 mg of tissue or 0.5 ml of 
plasma) were added with internal standards (D4-17b-E, 1 ng/sample; D9-
PROG, 0.2 ng/sample; D4-PREG, 5 ng/sample) and homogenized in 2 ml of 
MeOH/acetic acid (99:1, v/v) using an ultrasonic homogenizer (Bransonic 
Ultrasonics). After an overnight incubation at 4°C, samples were 
centrifuged at 12,000 rpm for 5 min and the pellet was extracted twice with 
1 ml of MeOH/acetic acid (99:1, v/v). The organic phases were combined 
and dried with a gentle stream of nitrogen in a 40°C water bath. Samples 
were resuspended with 3 ml of MeOH/H2O (10:90, v/v) and passed through 
an SPE cartridge. Steroids were eluted in MeOH, concentrated and 
transferred into auto-sampler vials before liquid chromatography–tandem 
mass spectrometry (LC–MS/MS) analysis. Quantitative analysis was 
performed on the basis of calibration curves prepared and analyzed using 
deuterated internal standards. Calibration curves were extracted as 
described above for samples. Positive atmospheric pressure chemical 
ionization (APCI) experiments were performed using a linear ion trap-mass 
spectrometer (LTQ, Thermo Electron) equipped with a Surveyor liquid 
chromatography Pump Plus and a Surveyor Autosampler Plus (Thermo 
Electron). The LC mobile phases were (A) H2O/0.1% formic acid and (B) 
methanol (MeOH)/0.1% formic acid. The gradient (flow rate 0.5 ml/min) was 
as follows:  
 T0.0 70% A  
 T1.5 70% A 
 T2.0 55% A 
 T3.0 55% A 
 T35.0 36% A 
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 T40.0 25% A 
 T41.0 1% A 
 T45.0 1% A 
 T45.2 70% A 
 T55.0 70% A 
The split valve was set at 0–6.99 min to waste, 6.99–43.93 min to source and 
43.93–55 to waste. The Hypersil Gold column (100 x 3 mm, 3 µm; Thermo 
Electron, USA) was maintained at 40°C. The injection volume was 25 µl and 
the injector needle was washed with MeOH/ water 1/1 (v/v). Peaks of the 
LC–MS/MS were evaluated using a Dell workstation by means of the 
software Excalibur release 2.0 SR2 (Thermo Electron). The mass spectrometer 
was operated in the positive ion mode with the APCI source using nitrogen 
as sheath, auxiliary and sweep gas at flow rates of 23, 8, 2 (arbitrary units), 
respectively. Other ion-source parameters: vaporizer temperature 450°C, 
ion-source collision-energy (SID) 20 V, capillary temperature 275°C. The 
mass spectrometer was used in MS/MS mode using helium as collision gas. 
The relative collision-energy was set at 35% for D4-17β-E, 3α-diol and at 35% 
using the Wide Band Activation mode (Thermo Electron) for all the other 
steroids. Samples were analyzed using the transitions previously reported by 
(Pesaresi et al., 2010). 
 
LIPIDOMIC ANALYSES ON PURIFIED MYELIN 
Myelin was purified from sciatic nerve of control, STZ, and STZ-treated with 
GW3965 rats as described by Norton and Poduslo in 1973 (Norton and 
Poduslo, 1973). 
Phospholipid, FA, and cholesterol extraction methods: Briefly their method 
was based on separation of different myelin structures using high speed 
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centifugation on sucrose gradient. Internal standards (Heneicosanoic acid, 
1500 ng/sample; 13C18-Linoleic acid, 500 ng/sample; 5α-Cholestane, 50 
µg/sample) were added to myelin samples, and lipid extraction was 
performed using two different extraction methods. The first separates lipidic 
molecules using Folch method [chloroform/MeOH 2:1, v/v], while the 
second extract lipids just adding methanol to the purified myelin. After 
extraction, in both these methods, samples were left overnight at 4°C. The 
organic residue was divided in two fractions: one for the analysis of free 
cholesterol and phospholipids (fraction A, 60% of the total sample), and the 
other for analysis of total FAs and total cholesterol (fraction B, 40% of the 
total sample). Total FAs and cholesterol were obtained from samples by 
acid hydrolysis (Taguchi and Ishikawa, 2010). Fraction B was resuspended in 
chloroform-MeOH 1:1, v/v. 1M HCl:MeOH (1:1, v/v) was added to the total 
lipid extract and shaken for 2 h. Chloroform-water (1:1, v/v) was added, 
and the lower organic phase was collected, transferred into tubes and 
dried under nitrogen flow. The residue was resuspended in 1ml of MeOH 
and splitted 60/40 for total FA and total cholesterol analysis, respectively. 
These two methods were proved to be efficient in lipidic molecules 
extraction from purified myelin. In fact the analyses performed showed no 
significant differences between samples prepared differently. 
Lipidomic profile by LC-MS/MS: Also lipidomic analyses has been performed 
using two different methods developed for two different instruments that 
has been used during both experiments. Method I has been optimized for 
analyses on a linear ion trap-mass spectrometer LTQ, (Thermo Electron, USA) 
while Method II has been developed on a different system that uses an API 
4000 triple quadrupole instrument (AB Sciex, USA). Even in this case the 
methods showed no differences between quantification of absolute values 
of myelin components. 
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Method I: The aliquot for FA quantification transferred into auto-sampler 
vials for LC-MS/MS analysis. Quantitative analysis was performed on the 
basis of calibration curves prepared and analyzed daily. Electrospray 
ionization (ESI) experiments were performed using a linear ion trap-mass 
spectrometer equipped with a Surveyor liquid chromatography Pump Plus 
and a Surveyor Autosampler Plus. The LC mobile phases were water and 
MeOH/2-propanol (50:50, v/v). The gradient (flow rate 0.2 ml/min) was as 
follows:  
 T 0 : 100% A 
 T 5 : 100% A 
 T 5.1 : 50% A 
 T 25 : 50% A 
 T 25.1 : 100% A 
 T 40 : 100% A 
The Hypersil GOLD TM pentafluorophenyl column (100mm × 2.1mm, 3μm) 
was maintained at 40°C and he injection volume was 20μl. Peaks area 
were evaluated using a Dell workstation by means of the software 
Excalibur, release 2.0 SR2. The mass spectrometer was operated in 
negative-ion mode with the ESI source using nitrogen as sheath, auxiliary, 
and sweeps gas, respectively. The mass spectrometer was operated in 
MS/MS mode using helium as a collision gas. The relative collision energy 
was set at 35% for all analyzed molecules.  
Method II: For FA quantification, aliquots of each sample (10 μl) were 
diluted 1:10 in MeOH/water (50:50 v/v), transferred into a 96 well plate and 
placed in an auto-sampler for LC-MS/MS analysis. Quantitative analysis was 
performed with calibration curves prepared and analyzed daily by 
electrospray ionization (ESI) using a triple quadrupole analyzer (API 4000, AB 
Sciex, USA). The LC mobile phases were: water/10mM 
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isopropylethylamine/15 mM acetic acid (phase A) and MeOH (phase B). 
The gradient (flow rate 0.5 ml/min) was as follows:  
 T 0: 20% A 
 T 20: 1% A 
 T 25: 1% A 
 T 25.1: 20% A 
 T 30: 20% A.  
The Hypersil GOLD C8 column (100 mm × 3 mm, 3 μm) was maintained at 
40°C. The mass spectrometer was operated in selective ion monitoring 
(SIM)/SIM mode. Peaks area were evaluated using a Dell workstation by 
means of the software Analyst release 4.1. The mass spectrometer was 
operated in negative-ion mode. 
Cholesterol quantification: Fractions for the quantitative analysis of free and 
total cholesterol, were first derivatized with a mixture of bis-
trimethylsilyltrifluoroacetamide-pyridine (4:1 v/v) for 30 min at 60°C, and 
then injected into a gas chromatograph-MS (GC-MS, Varian Saturn 2100). 
The MS was operated in the electron impact ionization mode. GC-MS 
analyses were performed as follows: 1µl sample was injected in splitless 
mode (inlet was kept at 270°C with the helium flow at 1.0 ml/min) at the 
initial 180°C. The oven was fi rst kept at 180°C for 1 min, ramped at 50°C/min 
to 240°C, then at 5°C/min to 300°C for 6 min. The ions used for the 
quantification of cholesterol were at m/z 368 for cholesterol and m/z 357 for 
5α-cholestane, the IS. The selection of ions for selective ion monitoring (SIM) 
analysis was based on mass spectra of pure compounds, and the 
quantification was based on calibration curves freshly prepared using a 
fixed concentration of the IS, and different increasing of cholesterol, in a 
range from 0 to 10 µg/µl. The amount of cholesteryl esters was calculated 
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by subtracting the amount of free cholesterol from total cholesterol. 
Cholesteryl esters were evaluated to verify the myelin quality and purity.  
Phospholipid analysis: ESI analysis of the major phospholipid classes was 
accomplished by utilization of either positive or negative ionization modes. 
Samples were directly infused for acquisition of MS/MS spectra. Changes 
between detected phospholipid families were calculated as percent of 
single phospholipid species normalized to total phospholipid analyzed. 
 
QUANTITATIVE REAL TIME PCR (RT-QPCR) 
RNA was prepared using the Nucleospin® RNA II kit (Macherey-Nagel; 
Milano, Italy). RNA was analyzed by TaqMan CFX384 RTqPCR using the 
iScriptTM one-step RT-PCR kit for probes (Bio-Rad; Milano, Italy). Samples 
were arrayed in 384-well format in triplicate as multiplexed reactions of 
target gene with 36B4 as reference gene. Probe and primer sequences 
were purchased from Eurofins MWG-Operon (Milano, Italy) and are 
available on request. 
 
TRANSFECTION AND PROTEIN ANALYSIS 
Expression constructs flag tagged for the mature forms of SREBP-1a, SREBP-
1c, and SREBP-2 were a gift of Dr. T. Osborne (Addgene plasmid #26801, 
#26802, and #26807, respectively; Addgene, Cambridge, MA). Five 
micrograms of each SREBP expression construct and 5 µg of pcDNA3 (the 
backbone plasmid of the SREBPs) were transfected individually in Hek293T 
cells using Fu- GENE 6 (Promega; Milano, Italia) according to manufacturing 
instructions in 6-well tissue culture plates. Six hours after transfection, the 
cells were cultured in DMEM with 10% FBS, and 48 h later, total protein 
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extracts were prepared using modifi ed RIPA buffer [50 mM Tris-HCl (pH 7.4), 
1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1mM EDTA, 
and protease inhibitor mixture (Roche; Monza, Italy)]. Western blotting was 
performed with a mouse monoclonal anti-SREBP-1 (Santa Cruz 
Biotechnology; Milano, Italy) at a dilution of 1:200, or a mouse polyclonal 
anti-Flag 1:1,000 (Sigma-Aldrich). Sciatic nerves from three different animals 
per experimental group were lysed using modified RIPA buffer. Western 
blotting was performed with a mouse monoclonal anti-SREBP-1 (Santa Cruz 
Biotechnology) at a dilution of 1:200, a rabbit polyclonal anti-P0 (Sigma-
Genosys; Milano, Italy) at a dilution of 1:500, or a rabbit polyclonal anti-
peripheral myelin protein 22 (PMP22) (Inbios; Napoli, Italy) at a dilution of 
1:5,000. As a loading control, membranes were probed with a mouse 
monoclonal anti-β-actin (Sigma-Aldrich) at a dilution of 1:1,000. All 
secondary antibodies were from Sigma-Aldrich. Quantification of protein 
levels was performed using Quantity One software (Bio-Rad). Analyses of 
protein levels were repeated at least three times with different sets of 
animals. 
 
MORPHOMETRIC ANALISYS  
Morphometric analyses were performed by Luis Miguel Garcìa Segura from 
Cajal Institute of Madrid. Sciatic nerves were removed, cut in segments (1–2 
mm length) and fixed by immersion in 1% paraformaldehyde and 1% 
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 24 h at 4°C. Tissue 
samples were washed in phosphate buffer, postfi xed for 2 h in 1% buffered 
OsO 4 , dehydrated, and embedded in araldite. Nerves were sectioned 
transversely using a Reichert Ultra-cut microtome. Semi-thin sections (0.5 
μm) were stained with toluidine blue and analyzed by light microscopy. Thin 
sections were examined using a JEOL 1200 EXII electron microscope. For 
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morphometric analysis of myelinated fi bers, areas of semithin sections, 
covering at least 25% of the total cross-sectional profile of the nerve, were 
chosen by systematic random sampling of squares (Mayhew et al., 1984). 
The size of axons, the g ratio, the percentage of normal and abnormal 
fibers, the percentage of fibers with infoldings and with alteration in myelin 
compaction, were analyzed using a JEOL 1200 EXII electron microscope. 
The g ratio was calculated as the quotient between the axon size and the 
fiber size (Arbuthnott et al., 1980). A minimum of 100 myelinated fibers were 
assessed from at least eight animals per group. 
 
ASSESSMENT OF PHYSIOLOGICAL PARAMETERS 
Thermal nociceptive threshold: Nociceptive threshold to radiant heat was 
quantified using the hot plate paw withdrawal test as previously described 
(Bianchi et al., 2004). Briefly, a 40 cm high Plexiglas cylinder was suspended 
over the hot plate and the temperature was maintained at 50±0.2°C. Paw 
withdrawal latency was defined as the time between placing the rat on 
the hot plate and the time of withdrawal, or licking of hindpaw, or 
discomfort manifested by the animal. The test was done every 2 weeks 
starting from the second week after STZ injection. Animals were tested 
twice, with a 30 min interval between tests.  
Nerve conduction velocity: At the end of treatment, antidromic tail NCV 
was assessed using a Myto EBNeuro electromyography apparatus as 
previously described (Meregalli et al., 2010). Briefly, recording ring 
electrodes were placed distally in the tail of Unanesthetized animals. The 
stimulating ring electrodes were placed 5 and 10 cm proximally with 
respect to the recording point. Latency of the potentials recorded at the 
two sites after nerve stimulation was determined (peak-to-peak, stimulus 
duration 100 ms, filter 1 Hz–5 MHz) and NCV calculated. All 
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neurophysiological studies were done under standard conditions in a 
temperature-controlled room adjacent to the animal housing room. Body 
temperature and vital conditions of the animals were monitored during the 
neurophysiological examination.  
Na+,K+-ATPase activity: Tibial stumps were dissected out, desheathed and 
homogenized in a chilled solution containing 0.25 M sucrose, 1.25 mM EGTA 
and 10 mM Tris, pH 7.5, at 1:20 (w/v) in a glass-glass Elvehjem–Potter 
homogenizer (DISA), and stored at -80°C for ATPase determinations. 
Na+,K+-ATPase activity was determined  spectrophotometrically as 
previously described (Bianchi et al., 2004). Protein content in homogenates 
was determined by Lowry’s method with bovine serum albumin as 
standard. 
STATISTICAL ANALYSES 
Statistical analyses were performed via one-way ANOVA followed by 
Tukey-Kramer posttest. All statistical analyses were performed with 
GraphPad PRISM version 5 (San Diego, CA). 
Principal component analysis was performed using Unscrambler, version 
10.1 (Camo Software; Oslo, Norway).  
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LXRS ARE ACTIVE IN SCIATIC NERVE 
To investigate the potential role of Liver X Receptors (LXRs) in diabetes-
induced peripheral neuropathy, we first assessed whether the two isoforms 
of LXR are expressed in peripheral nerve, such as the sciatic nerve, and 
whether their levels change in diabetic rats. LXRα and LXRβ are both 
expressed in rat sciatic nerve and their mRNA levels are unaffected by 
diabetes (Fig. 1).  
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Figure 1: LXRα and LXRβ are expressed in sciatic nerve and their levels are 
unaffected by diabetes. The bars represent the relative mRNA expression of shown 
genes normalized to the housekeeping gene 36B4. Data are presented as mean 
±SEM (n=9). 
 
LXRβ is the dominant isoform present in sciatic nerve. The expression of LXRα 
and LXRβ in sciatic nerve is substantially lower than that in liver, a tissue with 
considerable LXR activity (Fig. 1).  
To establish whether the levels of LXR present in sciatic nerve have 
functional significance, we measured LXR target gene expression after 
administration of a synthetic LXR ligand. GW3965 was given once a week 
for a month to STZ-treated rats 2 months after the induction of diabetes. 
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Expression of two bona fide LXR target genes involved in cholesterol efflux 
such as ATP Binding Cassette A1(ABCA1) and ATP Binding Cassette G1 
(ABCG1), which are not regulated in sciatic nerve in this model of diabetes, 
was significantly increased after treatment with GW3965 (Fig. 2a), indicating 
that LXRs are active transcriptional regulators in sciatic nerve. Notably, 
diabetes did not regulate the expression of both ABCA1 and ABCG1. In 
contrast, GW3965 treatment did not affect expression of key regulators of 
cholesterol synthesis, such as HydroxyMetylGlutaryl Coenzime A (HMGCoA) 
reductase and Sterol Regulatory Element Binding protein 2 (SREBP-2) (Fig. 
2b). 
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Figure 2: a) LXR activation by GW3965 treatment induces mRNA levels of ABCA1 
and ABCG1, classical LXR target genes involved in cholesterol efflux in the sciatic 
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nerve. These data indicate that the ligand reaches the sciatic nerve and that the 
LXRs are activated. b) Expression levels of HMGCoA reductase and SREBP-2, two 
genes involved in cholesterol synthesis. The mRNA levels of these genes are 
unchanged by diabetes and/or by GW3965 treatment. The bars represent the 
relative mRNA expression of shown genes normalized to the housekeeping gene 
36B4. Data are presented as mean ±SEM (n=9). Statistical analysis is performed by 
one-way ANOVA followed by Tukey–Kramer posttest. *p<0.05, **p<0.001 vs 
control; #p<0.05, ##p<0.001 vs STZ-treated rats.  
 
ACTIVATION OF LXR MODULATES NEUROACTIVE STEROID LEVELS 
Compared with normoglycemic controls, diabetic rats showed notable 
differences in the expression of several important genes involved in 
steroidogenesis and neuroactive steroids metabolism. In particular, mRNA 
levels of Steroidogenic Acute Regulatory Protein (StAR) and Translocator 
Protein 18KDa (TSPO) (proteins involved in cholesterol shuttling into the 
mitochondria), Cytochrome P450 Side Chain Cleavage (P450scc) (the 
enzyme responsible of the conversion of cholesterol into pregnenolone), 
and 5α Reductase (5α-R) (which converts progesterone and testosterone 
into their 5α-reduced metabolites, dihydroprogesterone and 
dihydrotestosterone respectively) were significantly decreased in the 
diabetic state (Fig. 3). Treatment of diabetic animals with an LXR activator 
restored mRNA levels of StAR, P450scc and 5α-R to the level observed in 
normoglycemic controls, but had no effect on TSPO expression (Fig. 3). 
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Figure 3: Gene expression of steroidogenic acute regulatory protein (StAR), 
translocator protein-18 kDa (TSPO), cytochrome P450 side chain cleavage 
(P450scc) and 5α reductase (5α-R), in sciatic nerve. As shown, LXR activation by 
GW3965 treatment in diabetic rats restores to normal levels the expression of StAR, 
P450scc and 5α-R but it does not affect TSPO levels. The bars represent the relative 
mRNA expression of shown genes normalized to the housekeeping gene 36B4. 
Data are presented as mean ±SEM (n=9). Statistical analysis is performed by one-
way ANOVA followed by Tukey–Kramer posttest. *p<0.05, **p<0.001 vs control rats; 
#p<0.05, ##p<0.001 vs STZ-treated rats. 
 
 In agreement with these gene expression patterns, we showed that 
diabetes decreased neuroactive steroid levels in sciatic nerve, and that 
treatment with an LXR ligand counteracted these effects. Indeed, LC–
MS/MS analysis showed that the levels of PREG, PROG, DHP, 
isopregnanolone, T and its derivatives, DHT and 5α-androstane-3α,17β-diol 
(3α-diol) were significantly decreased in the sciatic nerve of diabetic rats 
(Table 1).  
5. Results 
 
   62 
 
Table 1: Analysis of neuroactive steroids levels by LC-MS/MS in sciatic nerves of 
control, STZ, and STZ rats treated with GW3965. Data are expressed as pg/mg of 
tissue and are represented by mean ± SEM. The n is 8 for control, 8 for STZ and 6 for 
STZ+GW3965. Statistical analysis was performed by one-way analysis of variance 
(ANOVA) followed by Tukey–Kramer post-test. *P<0.05, **P<0.001 vs. control rats 
#P<0.05, ##P<0.001 vs. STZ treated rats. 
 
LXR activation completely reversed the diabetes induced decrease in 
PREG, PROG, DHP and 3α-diol levels. Interestingly, the levels of these 
neuroactive steroids also fell in the plasma of diabetic rats, but treatment 
with the LXR agonist had no effect on them (Table 2). 
 
Table 2: Analysis of neuroactive steroids levels by LC-MS/MS in plasma of control, 
STZ, and STZ rats treated with GW3965. Data are expressed as pg/mg of tissue and 
are represented by mean ± SEM. The n is 8 for control, 8 for STZ and 6 for 
STZ+GW3965. Statistical analysis was performed by one-way analysis of variance 
(ANOVA) followed by Tukey–Kramer post-test. *P<0.05, **P<0.001 vs. control rats. 
 
 
 PREG PROG DHP THP ISOPREG DHEA T DHT 3 -diol 
CTRL 1.52+0.23 1.58+0.22 8.86+0.59 1.00+0.16 2.19+0.38 0.24+0.04 1.52+0.23 0.80+0.11 1.01+0.13 
STZ 0.63+0.05* 0.62+0.09* 5.89+0.24** 0.65+0.03 0.61+0.07** 0.17+0.02 0.24+0.05** 0.18+0. 03** 0.57+0.10* 
STZ 
+GW 
1.45+0.33# 1.71+0.24## 9.17+0.59## 0.92+0.05 1.07+0.06* 0.29+0.04 0.27+0.13** 0.20+0.04** 1.09+0.13# 
 PREG PROG DHP THP ISOPREG DHEA T DHT 3 -diol 
CTRL 0.64+0.07 0.82+0.12 1.22+0.11 0.49+0.10 0.33+0.10 0.059+0.007 4.12+0.57 0.065+0.006 1.63+0.27 
STZ 0.32+0.09* 0.28+0.05** 0.83+0.04* 0.36+0.12 0.28+0.09 0.058+0.009 0.70+0.021** 0.064+0. 01 0.54+0.13** 
STZ 
+GW 
0.29+0.03* 0.68+0.19 0.78+0.16* 0.75+0.17 0.68+0.19 0.065+0.008 0.25+0.08** 0.055+0. 005 0.71+0.21* 
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LXR ACTIVATION REDUCE DIABETES-INDUCED NEUROPATHY 
Since activation of LXRs in diabetic sciatic nerves restored neuroactive 
steroid levels to a near-normal state, we examined whether this LXR-
mediated increase could be associated with a neuroprotective effect. 
Table 3 shows that 3 months after the induction of diabetes, STZ-treated rats 
had higher blood glucose and significantly lower weight than non-diabetic 
control rats. 
              
Table 3: Body weight and blood chemistry of control, STZ and STZ rats treated with 
GW3965. Legend: Data are expressed as the mean ±SEM, n=14. Statistical analysis 
is performed by one-way analysis of variance (ANOVA) followed by Tukey–Kramer 
post-test. *P<0.05, **P<0.001 vs. control rats. NEFA are non-esterified fatty acids. 
 
Plasma levels of triglycerides and nonesterified fatty acids were unaffected 
by diabetes. Treatment with GW3965, an LXR agonist, had no effect on 
these parameters. However, LXR activation did result in significant 
neuroprotective effects as measured by functional and biochemical tests. 
Treatment with GW3965 was able to significantly reduce the increase in 
thermal sensitivity brought about by diabetes (Fig. 4). 
 In addition to this decrease in thermal nociceptive threshold in LXR ligand-
treated animals, we also observed that antidromic tail nerve conduction 
velocity (NCV), which is significantly reduced by diabetes, was enhanced 
 CTRL STZ STZ + GW 
Weight (grams) 524.1±60.4 270.4±46.4** 288.8±50.4** 
Glycemia (mg/dl) 84.2±19.2 953.1±238.1** 949.7±207.9** 
Triglycerides (mg/dl) 68.9±19.2 83.6±38.6 89.5±47 
NEFA (meq/l) 0.70±0.24 0.67±0.31 0.72±0.28 
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by LXR ligand treatment. Moreover, treatment with the LXR agonist reverted 
the reduction in Na+, K+-ATPase activity in sciatic nerve brought about by 
diabetes (Fig. 4). 
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Figure 4: Thermal sensitivity, nerve conduction velocity, and Na+, K+-ATPase 
activity in control, STZ and STZ treated with GW3965 rats. Data are expressed as 
withdrawal latency in seconds for heat sensitivity threshold (control, n=10, STZ, 
n=12; STZ+GW3965, n=14), as m/s for NCV (control, n=14; STZ, n=12; STZ+GW3965, 
n=14) and as μmol Pi/h per mg protein for Na+, K+-ATPase (control, n=6; STZ n=7; 
STZ + GW3965, n=6), and are mean ±SEM. Statistical analysis is performed by one-
way ANOVA followed by Tukey–Kramer posttest. *p<0.05, **p<0.001 vs control rats; 
#p<0.05, ##p<0.001 vs STZ-treated rats. 
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LXR ACTIVATION REVERT CHANGES IN MYELIN LIPID 
COMPOSITION INDUCED BY DPN 
We have shown that treatment of STZ-treated rats with a synthetic liver X 
receptor (LXR) ligand promotes cholesterol utilization and increases 
neuroactive steroid levels in sciatic nerve, resulting in significant 
improvements in physiological parameters brought down by diabetes. 
Moreover LXR is able to regulate the expression of Sterol Regulatory Element 
Binding Factor 1C (SREBP-1C). This transcription factor is one of the most 
important regulator in lipid biosynthesis. Here, we report that rats with DPN 
display an altered myelin lipid composition pattern, blunted expression of 
key genes in the Fatty Acids (FA) biosynthetic pathway, and decreased 
levels of the active form of the lipogenic transcription factor SREBP-1c and 
the chief myelin protein zero (P0). These defects are associated with 
increased myelin infoldings in the sciatic nerve of diabetic rats. Activation 
of LXR with a synthetic ligand normalizes myelin’s lipid profile, restores 
expression of genes involved in FA biosynthesis, reestablishes nuclear levels 
of SREBP-1c and absolute levels of P0, and corrects the major myelin 
abnormalities induced by diabetes in peripheral nerves. These changes are 
associated with improved performance in functional tests. 
Diabetes was induced in adult Sprague-Dawley rats by a single STZ 
injection. To explore the role of myelin lipids in the pathogenesis of DPN, 
and to evaluate whether LXR activation (through its ability to induce the 
master regulator of lipogenesis, SREBP-1c) could play a role, we compared 
age-matched nondiabetic and STZ-treated rats dosed with either vehicle or 
the synthetic LXR ligand GW3965 once a week for a month, starting two 
months after the induction of diabetes. Three months after the induction of 
diabetes, both groups of STZ-treated rats showed decreased body weight 
and increased glycemia relative to nondiabetic controls (Table 3). As 
previously demonstrated, diabetes affected functional parameters such as 
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thermal nociceptive threshold and nerve conduction velocity, indicating 
that the animals developed peripheral neuropathy. LXR activation reversed 
these diabetes-induced peripheral nerve deficits (Fig. 4).   
To test the hypothesis that diabetes induces an altered lipid composition 
profile in peripheral nerves, we performed detailed lipidomic analyses on 
sciatic nerve myelin purified from control, STZ, and STZ-GW3965-treated rats. 
The phospholipid families profile of purified myelin revealed that diabetes 
primarily decreases the levels of glycosphingolipids (GSLs), whereas 
phosphatidyl serine (PS) and phosphatidyl choline (PC) were mildly 
increased (Fig. 6). Levels of phosphatidyl ethanolamine (PE), phosphatidyl 
inositol (PI), sphingomyelin (SM), and sulfatides (Sulf) were unchanged (Fig. 
6).  
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Figure 6: Percent of detected phospholipid families of sciatic nerve purified myelin 
from control, STZ and STZ-treated with GW3965 animals. Statistical analysis was 
performed by one-way ANOVA followed by Tukey-Kramer posttest. Data are 
expressed as mean ±SEM. n=11 animals per group. *P<0.05, **P<0.001 vs. control 
rats; #P<0.05, ##P<0.001 vs. STZ-treated rats. PE, phosphatidyl ethanolamine; PC, 
phosphatidyl coline; PS, phosphatidyl serine; PI, phosphatydil inositol; SM, 
sphingomyelin; GSL, glycosphingolipid; Sulf, sulfatide. 
 
We also detected a 60% decrease in sciatic nerve myelin cholesterol 
content (Fig. 7). Remarkably, LXR activation in this diabetic setting restored 
the levels of all these lipids to those found in the nondiabetic control group 
(Fig. 6, 7).  
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Figure 7: Cholesterol levels of sciatic nerve purified myelin from control, STZ and 
STZ-treated with GW3965 animals. Statistical analysis was performed by one-way 
ANOVA followed by Tukey-Kramer posttest. Data are expressed as mean ±SEM. 
n=11 animals per group. *P<0.05, **P<0.001 vs. control rats; #P<0.05, ##P<0.001 vs. 
STZ-treated rats.  
 
Next, we evaluated the FA composition of the analyzed phospholipids 
families in purified myelin. Principal component analysis of myelin FAs 
revealed two separate clusters: the first includes control and STZ-GW3965-
treated rats and the second the STZ diabetic animals (Fig. 8a, 8b). 
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Figure 8: Principal component analysis of sciatic nerve purified myelin from 
control, STZ, and STZ-treated with GW3965 animals. a): Score plot of the lipid 
composition analysis of five animals per group. The two coordinates (Principal 
Component 1 and Principal Component 2) represent together >80% of the 
variance of these 15 samples. Principal Component 1 accounts for 73% of this 
variance and clearly identifies two clusters. The first includes the control and STZ-
GW3965 animals (red circle), whereas the diabetic rats (blue circle) belong to the 
second cluster, indicating that the lipid profile is different between the two clusters. 
b): Correlation loadings plot computed for each FA analyzed for the displayed 
principal components. The red circle (control and STZGW3965-treated groups) and 
the blue circle (STZ-vehicle treated group) represent the FAs enriched in the 
considered cluster. For instance, 18:0 may be considered a marker for the STZ 
group, whereas 18:1 is a marker for control and STZ-GW3965-treated animals. The 
two ellipses indicate how much variance is taken into account. The outer ellipse 
accounts for 100% of explained variance. The inner ellipse shows 50% of explained 
variance. 
 
a 
b 
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Moreover, the correlation graph showed each FA analyzed associated to 
the two identified clusters (Fig. 8b). These plots and the myelin FA 
quantifications (Fig. 9) indicate that diabetes led to increased levels of 
saturated stearic (C18:0), behenic (C22:0), and lignoceric (C24:0) acids, 
whereas monounsaturated oleic acid (C18:1), nervonic acid (C22:1), and 
erucic (C24:1) acid decreased (Figs. 9, 8a, 8b), indicating the inability of 
vehicle-treated diabetic rats to desaturate FAs. In addition, γ-linolenic acid 
(C18:3) was decreased in STZ rats, but arachidonic (C20:4), 
eicosapentaenoic (C20:5), and docosahexaenoic (C22:6) acids were 
increased (Figs. 9, 8a, 8b). All changes in FA levels induced by diabetes 
were restored to normal levels by LXR activation (Figs. 9, 8a, 8b). 
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Figure 9: FA profile of sciatic nerve purified myelin from control, STZ and STZ-treated 
with GW3965 animals. Statistical analysis was performed by one-way ANOVA 
followed by Tukey-Kramer posttest. Data are expressed as mean ±SEM. n=11 
animals per group. *P<0.05, **P<0.001 vs. control rats; #P<0.05, ##P<0.001 vs. STZ-
treated rats. 
 
 Furthermore, in diabetic animals, we detected a significant shift in the 
levels of monounsaturated FAs toward PUFAs (Fig. 10), along with an 
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increased ratio of C18:0/C18:1 corresponding to a decreased desaturation 
index (Fig. 11).  
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Figure 10: Levels of monounsaturated and polyunsaturated FAs of sciatic nerve 
purifyed myelin from control, STZ and STZ-treated with GW3965 animals. Statistical 
analysis was performed by one-way ANOVA followed by Tukey-Kramer posttest. 
Data are expressed as mean ±SEM. n=11 animals per group. *P<0.05, **P<0.001 vs. 
control rats; #P<0.05, ##P<0.001 vs. STZ-treated rats.  
 
In addition, diabetes also decreased the C18:1/ C18:2 ratio, an index 
correlating with altered membrane fluidity (Fig. 11) (Chrast et al., 2011). LXR 
activation once again brought the levels of these FAs to those of control 
rats and normalized both desaturation and membrane fluidity indexes (Fig. 
10, 11). 
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Figure 11: A) Desaturation index as ratio of C18:0 (stearic acid)/C18:1 (oleic acid) 
and B) membrane fluidity as ratio of C18:1 (oleic acid)/C18:2 (linoleic acid) of 
sciatic nerve purified myelin from control, STZ and STZ-treated with GW3965 
animals. Statistical analysis was performed by one-way ANOVA followed by 
Tukey-Kramer posttest. Data are expressed as mean ±SEM. n=11 animals per 
group. *P<0.05, **P<0.001 vs. control rats; #P<0.05, ##P<0.001 vs. STZ-treated rats. 
 
 We also identified FA species such as C18:1 and C18:3 that are primarily 
associated with the most abundant glycosphingolipids (PC and GSL, Fig. 6), 
as being less represented in the diabetic group relative to normal and 
diabetic GW3965-treated animals (Fig. 12).  
A B 
5. Results 
 
   73 
16
:0
/1
8:
1 
P
C
20
:4
/1
8:
2 
P
C
18
:1
/1
8:
1 
P
S
16
:0
 G
SL
18
:1
 G
SL
18
:3
 G
SL
0
4
8
12
16
Control STZ STZ+GW3965
*
#
* #
*
*
#**
#
C
o
n
tr
ib
u
ti
o
n
 t
o
  
p
h
o
s
p
h
o
li
p
id
s
 (
%
)
 
Figure 12: FAs associated to the significantly different phospholipids of sciatic 
nerve purified myelin from control, STZ and STZ-treated with GW3965 animals. 
Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer 
posttest. Data are expressed as mean ±SEM. n=11 animals per group. *P<0.05, 
**P<0.001 vs. control rats; #P<0.05, ##P<0.001 vs. STZ-treated rats. 
 
Importantly, the lipid profile changes observed in diabetic rats were not 
detected in plasma, indicating that the effects of diabetes on lipogenesis 
occur locally in the sciatic nerve (data not shown). Taken together, these 
results indicate that myelin from diabetic animals has a different lipid 
composition pattern and that treatment with an LXR ligand, a lipogenic 
stimulus, restores the lipid profile to that of non-diabetic controls.  
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LXR ACTIVATION RESTORES EXPRESSION OF KEY GENES IN FA 
BIOSYNTHESIS SUPPRESSED BY DIABETES 
To better understand the observed changes in myelin lipid profiles, the 
mRNA level of genes involved in lipid biosynthesis were analyzed in the 
sciatic nerve of control, STZ, and STZ-GW3965-treated rats. We found that 
lipogenic genes such as SREBP-1c, acetyl-CoA carboxylase α (ACACA), 
FAS, SCD-1, and -2 [SCD-2, the main isoform expressed in peripheral nerves 
(Garbay et al., 1998), and FA desaturase-1 and -2, were all downregulated 
in diabetic sciatic nerve, and that their expression was brought back to 
nondiabetic levels by pharmacologic LXR activation (Fig. 13). Expression of 
enzymes involved in FA elongation, such as elongase of very long chain FAs 
5 and 6, (Elovl 5 and 6) were unchanged in all experimental groups (Fig. 
13).  
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Figure 13: Expression profile of FA biosynthesis genes. Statistical analysis was 
performed by one-way ANOVA followed by Tukey-Kramer posttest. The bars 
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represent the relative mRNA expression of shown genes normalized to the 
housekeeping gene 36B4. Data are expressed as mean ±SEM. n=8 animals per 
group. *P<0.05, **P<0.001 vs. control rats; #P<0.05, ##P<0.001 vs. STZ-treated rats. 
 
As expected, non-diabetic rats treated with GW3965 also showed 
increased expression of SREBP-1c, FAS, and SCD-1 and -2 compared with 
nondiabetic rats receiving vehicle (data not shown). However, in this 
nonpathological setting, these changes in gene expression are not 
sufficient to significantly affect myelin lipid composition (data not shown). 
These findings show that pharmacological LXR activation can restore the 
levels of key genes involved in lipid synthesis whose expression is suppressed 
in the sciatic nerve of diabetic animals. 
 
ACTIVATION OF LXR RESTORES TRANSCRIPTIONALLY ACTIVE 
SREBP1-C 
Because SREBP-1c is a classic LXR target gene and all FA biosynthesis genes 
affected by diabetes are known to be regulated by this lipogenic 
transcription factor (Shimomura et al., 1999), we measured the levels of the 
cytoplasmic precursor and the mature nuclear form of SREBP-1c. The 
precursor form of SREBP-1c is anchored in endoplasmic reticulum 
membranes. Upon stimulation (e.g., insulin, in the case of SREBP-1c), the 
precursor is cleaved into a mature form that shuttles to the nucleus to 
activate expression of enzymes involved in FA biosynthesis (Wang et al., 
1994). We found that the sciatic nerve of diabetic animals contains less 
transcriptionally active SREBP-1 (mature form), a decrease that is rescued 
by LXR activation (Fig. 14). 
5. Results 
 
   76 
 
Ctrl STZ STZ+GW Ctrl STZ STZ+GW
0.2
0.4
0.6
0.8
1.0
0
Srebp1 precursor Srebp1 cleaved
*
#
ra
ti
o
  
S
re
b
p
1
/
-a
c
ti
n
 
Figura 14: Representative Western blot analysis and quantification of SREBP-1c 
precursor (125 kDa) and transcriptionally active form (cleaved, 68 kDa) in control, 
STZ, and STZ-treated with GW3965 rat sciatic nerve. 
 
 The SREBP-1 antibody used was validated using extracts from HEK293T cells 
transfected with Flag-tagged expression constructs for the mature forms of 
SREBP-1a (Toth et al., 2004), SREBP-1c (Toth et al., 2004), and SREBP-2 (Jeon 
et al., 2008). The SREBP-1 antibody detected the mature forms of SREBP-1a 
and SREBP-1c, but it did not cross-react with SREBP-2 (data not shown). To 
exclude a role for SREBP-1a, we measured the mRNA levels of this 
transcription factor. Expression of SREBP-1a was not affected by diabetes or 
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treatment with the LXR agonist GW3965 (data not shown). These results 
indicate that SREBP-1c is the isoform most affected by DPN. 
 
LXR ACTIVATION IMPROVES MYELIN PROTEIN COMPOSITION 
In addition to lipids, myelin is composed of about 20–30% protein. We found 
that the levels of P0 protein, which represent between 50% and 70% of total 
myelin protein in peripheral nerves (Garbay et al., 2000), were decreased 
by diabetes (Fig. 15), confirming data already present in the literature 
(Mayhew ey al., 1984) Pharmacological LXR activation restored P0 levels to 
those found in nondiabetic control rats; levels of PMP22 were unchanged 
among experimental groups (Fig. 15). 
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Figura 15: Myelin protein analysis. Representative P0 and PMP22 Western blot 
analyses and relative quantifications. Statistical analysis was performed by one-
way ANOVA followed by Tukey-Kramer posttest. Data are expressed as mean 
±SEM. n=3 animals per group. *P<0.05 vs. control rats; #P<0.05 vs. STZ-treated rats. 
 
THE SCIATIC NERVE OF STZ-TREATED DIABETIC RATS SHOWS 
MYELIN ABNORMALITIES THAT CAN BE REVERSED BY LXR 
ACTIVATION  
To investigate whether the observed effects on myelin lipid and protein 
composition induced by diabetes are associated with myelin abnormalities, 
P0 PMP22 
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we performed morphometric and morphological analyses. We observed 
that myelin fibers from diabetic animals have a reduction in normal fibers 
and show increased myelin abnormalities (Fig. 16). These pathological 
changes were reversed to what is seen in nondiabetic animals by 
treatment with the LXR ligand (Fig. 16).  
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Figura 16: Morphometric and TEM analysis of myelinated fibers in sciatic nerve of 
control, STZ, and STZ-treated with GW3965 rats. a): Percentage of normal fibers. b): 
Percentage of abnormal fibers. Statistical analysis was performed by one-way 
ANOVA followed by Tukey-Kramer posttest. Data are expressed as mean ±SEM. 
n=8 animals per group. **P<0.001 vs. control rats; #P<0.05 and ##P<0.001 vs. STZ-
treated rats. 
 
In particular, the diabetic state increased myelin infoldings, and these were 
restored to normal levels by LXR ligand treatment (Fig. 17).  
a b 
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Figura 17: Morphometric and TEM analysis of myelinated fibers in sciatic nerve of 
control, STZ, and STZ-treated with GW3965 rats. Percentage of fibers with myelin 
infoldings. Statistical analysis was performed by one-way ANOVA followed by 
Tukey-Kramer posttest. Data are expressed as mean ±SEM. n=8 animals per group. 
**P<0.001 vs. control rats; #P<0.05 and ##P<0.001 vs. STZ-treated rats. 
 
Percentage of alterations in myelin irregular fiber shape and compaction 
(Fig. 18a, 18b), as well as g-ratio and axonal diameter (Fig. 18c, 18d), were 
similar among experimental groups 
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Figura 18: Morphometric and TEM analysis of myelinated fibers in sciatic nerve of 
control, STZ, and STZ-treated with GW3965 rats. a): Percentage of fibers with myelin 
irregular shapes. b): Percentage of fibers with alterations in myelin compaction c): 
g-ratio of myelinated fibers d): Axonal diameter. Statistical analysis was performed 
by one-way ANOVA followed by Tukey-Kramer posttest. Data are expressed as 
mean ±SEM. n=8 animals per group. **P<0.001 vs. control rats; #P<0.05 and 
##P<0.001 vs. STZ-treated rats. 
 
Myelin ultrastructure studies using transmission electron microscopy (TEM) 
confirmed observations from myelin fiber analysis (Fig. 19).  
a b 
c d 
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Figura 19: Morphometric and TEM analysis of myelinated fibers in sciatic nerve of 
control, STZ, and STZ-treated with GW3965 rats. H: Detail of myelinated nerves 
analyzed by TEM. Myelin infoldings are observed in diabetic rats (asterisks). Scale 
bars: 8 µm. 
These data show that STZ-induced peripheral neuropathy is characterized 
by myelin abnormalities such as infoldings, which are reversed to control by 
activation of LXR. 
 
DIABETES INDUCED AN ALTERED MYELIN LIPID PROFILE IN THE 
SCIATIC NERVE 
Till now has been underlined the protective effects of neuroactive steroids 
(Melcangi and Panzica, 2009) on peripheral nerves and these results 
allowed us to associate these observations with effects obtained after LXR 
activation. Alltoghether this led us to study whether neuroactive steroids 
may exert their protective effects on DPN by regulating myelin lipid profile, 
through the regulation of fatty acid biosynthetic pathway and ultimately 
protecting myelin structure and function. In this study we focus our attention 
on DHP or 3α-diol, two neuroactive steroids restored to control levels by LXR 
activation (Tab. 1). 
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As reported in Table 4, three months after the induction of diabetes, all the 
experimental groups of STZ-treated rats showed decreased body weight 
and increased glycemia relative to non-diabetic controls. In agreement 
with our previous findings (Fig. 4), diabetes affected functional parameters 
such as thermal nociceptive threshold (Table 4) and the treatment with DHP 
or 3α-diol partially reverted this diabetes-induced peripheral nerve deficit. 
 CTRL STZ STZ + DHP STZ +3α-diol 
Weight (grams) 532.5±11.3 317.5±31.3** 291.4±13.8** 293.3±19.9** 
Glycemia (mg/dl) 180±14.7 701.5±17.4** 677±36.7** 700.6±22.3** 
Thermal 
nociceptive 
threshold (sec.) 
11.2±0.88 34.6±2.3** 19.8±1.3*## 19.4±3.4*## 
Table 4: Body weight, glycemia (fed) and thermal nociceptive threshold of control 
and STZ rats treated with vehicle, DHP or 3α-diol. Data are expressed as the mean 
±SEM, n=7-10 rats per experimental group. Statistical analysis is performed by one-
way analysis of variance (ANOVA) followed by Tukey–Kramer post-test. *P<0.05, 
**P<0.001 vs. control group; ##P<0.001 vs. STZ group. 
 
To test whether DHP and/or 3α-diol may reduce the altered lipid pattern 
induced by diabetes in peripheral myelin, we performed detailed lipidomic 
analyses on sciatic nerve myelin purified from control, STZ, STZ-DHP and STZ-
3α-diol treated rats. We first focused our attention on total fatty acids, 
confirming our previous observations on the effects exerted by diabetes 
(Fig. 20). These data were obtained with the different method of lipid 
extraction, however both the experiments showed comparable fatty acids 
quantifications and for this reason they can be used indistinctly. 
Diabetic animals showed increased levels of saturated stearic acid (C18:0) 
and this was associated with decreased levels of the corresponding 
monounsaturated oleic acid (C18:1) (Fig. 20). In addition, γ-linolenic acid 
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(C18:3) levels were decreased in STZ rats, while arachidonic acid (C20:4) 
levels, a metabolite of C18:3, were increased (Fig. 20).  
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Figure 10: Lipidomic profile of sciatic nerve purified myelin from non-diabetic 
control, STZ and STZ-treated DHP or 3α-diol. Total fatty acid profile of myelin purified 
from the three experimental group. Statistical analysis was performed by one-way 
ANOVA followed by Tukey-Kramer post test. Data are expressed as mean ±SEM. 
n=7-10 animals per group. *P<0.05, **P<0.001 vs. control rats; #P<0.05, ##P<0.001 
vs. STZ-treated rats. 
 
These changes were suggestive of the inability to properly desaturate fatty 
acids in vehicle-treated diabetic rats. Indeed, diabetes induced an 
increased ratio of C18:0/C18:1, corresponding to an altered desaturation 
index (Fig. 21) as well as a decreased ratio of the C18:1/C18:2, an index 
correlating with changes in membrane fluidity (Fig. 21) (Chrast et al., 2011). 
In addition, diabetes reduced cholesterol levels in myelin. (Fig. 21). 
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Figure 21: Lipidomic profile of sciatic nerve purified myelin from non-diabetic 
control, STZ and STZ-treated DHP or 3α-diol. a): Desaturation index as ratio of C18:0 
(stearic acid)/C18:1 (oleic acid) and b): membrane fluidity index as ratio of C18:1 
(oleic acid)/C18:2 (linoleic acid). c): Myelin cholesterol levels. Statistical analysis 
was performed by one-way ANOVA followed by Tukey-Kramer post test. Data are 
expressed as mean ±SEM. n=7-10 animals per group. *P<0.05, **P<0.001 vs. control 
rats; #P<0.05, ##P<0.001 vs. STZ-treated rats. 
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TREATMENTS WITH DHP OR 3α-DIOL PARTIALLY NORMALIZED TO 
CONTROL VALUES THE MYELIN LIPID PROFILE IN THE SCIATIC 
NERVE OF DIABETIC RATS 
The altered lipid pattern induced by diabetes in the myelin of the sciatic 
nerve was partially restored to non-diabetic control values by the treatment 
with DHP or 3α-diol.  DHP and 3α-diol treated rats showed normal levels of 
stearic acid (C18:0), oleic acid (C18:1) (Fig. 20) and normalized values of 
the C18:0/C18:1 and C18:1/C18:2 ratios (Fig. 21).  In contrast, neither DHP 
nor 3α-diol were able to restore the cholesterol levels (Fig. 21) and γ-
linolenic acid (C18:3) while its metabolite arachidonic acid (C20:4) was 
normalized to control values (Fig. 20). 
 
DIABETES DECREASED THE EXPRESSION OF KEY GENES INVOLVED 
IN FATTY ACID BIOSYNTHESIS AND THIS EFFECT WAS 
COUNTERACTED BY THE TREATMENTS WITH DHP OR 3α-DIOL 
To substantiate the detected changes in myelin lipid profiles, and to 
provide evidence that the two neuroactive steroids may modulate fatty 
acid biosynthesis we measured the mRNA level of genes encoding 
molecules or enzymes involved in the de novo lipogenic pathway. We 
observed that the expression of a major lipogenic transcription factor gene, 
such as the sterol regulatory element binding protein-1c (SREBP-1c), as well 
as the expression of enzymes, such as acetyl-CoA carboxylase α (ACC), 
fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1) and fatty acid 
desaturase 1 and 2 (FADS1 and FADS2), were down-regulated in diabetic 
sciatic nerve, and were brought back to non-diabetic levels by treatment 
with DHP or 3α-diol (Fig. 22). 
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Figura 22: Expression analyses of fatty acid biosynthesis genes. Statistical analysis 
was performed by one-way ANOVA followed by Tukey-Kramer post-test. Data are 
expressed as mean ±SEM. n=7-10 animals per group. **P<0.001 vs. control rats; 
#P<0.05, ##P<0.001 vs. STZ-treated rats. 
 
On the contrary, expression of enzymes involved in fatty acid elongation, 
such as elongase of very long chain fatty acids 5 and 6 (Elovl 5 and Elovl 6), 
were unchanged in all experimental groups (data not shown).  
 
TREATMENT WITH DHP OR 3α-DIOL REDUCED MYELIN 
ALTERATIONS INDUCED BY DIABETES 
The diameter and the total number of myelinated fibers were not affected 
neither by diabetes nor by treatments (data not shown). However, we 
observed that myelinated fibers from diabetic animals had increased 
numbers of myelin infoldings (Fig. 23), a deleterious effect restored to 
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normal levels by DHP or 3α-diol administration (Fig. 23). In addition, the g-
ratio was similar among experimental groups (Fig. 23), indicating that 
diabetes does not influence myelination per se but only the lipid 
composition of the sheath. 
  
CTRL STZ DHP 3 DIOL
0
1000
2000
3000
4000
***
### ###
M
y
e
li
n
a
te
d
 f
ib
e
rs
 w
it
h
 i
n
fo
ld
in
g
s
CTRL STZ DHP 3 DIOL
0.0
0.2
0.4
0.6
0.8
g
-r
a
ti
o
E F
 
Figure 23: Morphometric and morphological analyses of myelinated fibers in the 
sciatic nerve of control, STZ, and STZ-treated with DHP or 3α-diol. Detail of 
myelinated nerves (A, control; B, STZ; C, STZ treated with DHP; D, STZ treated with 
3α-diol). Myelin infoldings are indicated in diabetic rats (arrowheads in panel B). 
Scale bar: 12 μm. E): Percentage of fibers with myelin infoldings. F): g ratio of 
myelinated fibers. Statistical analysis was performed by one-way ANOVA followed 
by Tukey-Kramer post-test. Data are expressed as mean ±SEM, n=6 animals per 
experimental group. **P<0.001 vs. control rats; ##P<0.001 vs. STZ-treated rats. 
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Diabetes is one of the leading cause of mortality worldwide. Chronic 
hyperglycemia usually results in complications such as high blood pressure, 
blindness, kidney malfunction, and nervous system disease (American 
Diabetes, 2007, Herman, 2007). Diabetic neuropathy appears frequently in 
patients diagnosed with either type 1 or type 2 diabetes; in fact, 60% to 70% 
of diabetics develop nerve injuries. Nerve malfunction and damage is 
primarily due to decreased blood flow and high blood glucose levels; the 
extent of abnormalities is more pronounced if the hyperglycemia is not 
controlled properly. Peripheral nerve injuries may affect cranial nerves or 
nerves from the spinal column and their branches (Sugimoto et al., 2000, 
Vinik et al., 2000). Neuroactive steroids have been shown to exert 
neuroprotective effects in experimental models of diabetic neuropathy 
(Leonelli et al., 2007). Has been recently shown that increasing cholesterol 
shuttling into the mitochondria using a TSPO ligand resulted in an increase in 
the low levels of neuroactive steroids present in the sciatic nerve of diabetic 
animals that was accompanied by nerve protective effects (Giatti et al., 
2009). In this research, we report similar findings using synthetic activator of 
the LXR nuclear receptors. The low levels of PREG (the first steroid hormone 
formed from cholesterol) measured in sciatic nerve of STZ-treated diabetic 
animals (Pesaresi et al., 2010) were increased upon LXR ligand treatment. 
LXR activation is known to play a role in steroidogenesis in the adrenal 
gland, directly regulating StAR expression, an important molecule involved 
in the initial process of steroidogenesis (Cummins and Mangelsdorf, 2006). In 
agreement with these results, we found that in peripheral nerves, such as 
the sciatic nerve, activation of LXR in the context of diabetes restores 
normal StAR mRNA levels. Moreover, we also found that the mRNA levels of 
P450scc, the enzyme converting cholesterol to PREG, were completely 
restored to physiological levels in STZ treated rats treated with GW3965. In 
contrast, TSPO expression was not influenced by treatment with GW3965. 
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Whether simultaneous activation of StAR and TSPO is necessary to activate 
steroidogenesis is a subject of debate (Bogan et al., 2007; Rone et al., 
2009). In our study, the normalization of StAR and P450scc mRNA levels may 
be sufficient to account for the increased levels of PREG measured in 
sciatic nerve. We also found restored levels of PROG and its metabolite 
DHP, as well as metabolites of T, such as 3α-diol, in the sciatic nerve of 
diabetic rats treated with the LXR ligand. At least in the case of PROG and 
DHP, the increased levels observed in LXR-treated diabetic rats may be due 
to greater availability of their precursors (e.g., PREG), as well as to increased 
expression of the enzyme that generates DHP (e.g., 5α-reductase). 
Interestingly, LXR activation did not affect plasma levels of PREG, PROG, 
DHP and 3α-diol demonstrating that the observed increase of neuroactive 
steroids levels was due to enhanced local production and not to uptake 
from the periphery. This observation is quite significant because increasing 
levels of neuroactive steroids directly in the nervous system and not in 
plasma, may avoid possible endocrine side effects exerted by these 
molecules.  
Because LXR activation restored local production of neuroactive steroids, 
we tested whether these effects resulted in neuroprotection in diabetic STZ-
treated rats. Treatment with an LXR ligand ameliorated the impairment in 
NCV, thermal threshold, and Na+, K+-ATPase activity brought about by the 
diabetic state.  
LXR activation may impact neuroactive steroid levels through its ability to 
regulate transcription of genes involved in cholesterol homeostasis. We 
demonstrated that the expressions of HMGCoA reductase and SREBP-2, key 
regulators of cholesterol synthesis, were unchanged among experimental 
groups, suggesting that the increased neuroactive steroid levels seen with 
LXR activation in the sciatic nerve is not related to the enhanced 
cholesterol synthesis. Thus, we hypothesize that the benefits of LXR 
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activation in this setting are due to a promotion of cholesterol utilization, 
similar to what showed in the adrenal gland (Cummins and Mangelsdorf, 
2006). In support of this idea, we observed an upregulation of cholesterol 
efflux genes, such as ABCA1 and ABCG1, in the sciatic nerve of animals 
treated with GW3965. These genes are direct LXR targets, and their 
induction would be expected to maintain the level of free cholesterol at a 
safe limit by promoting cholesterol efflux. In summary, as shown in Figure 24, 
we demonstrated that LXR activation in a diabetic setting that result in 
peripheral neuropathy can have a beneficial effect.  
                    
Figure 24: Proposed model of LXRs activation in diabetic neuropathy. The entrance 
of cholesterol into mitochondria is accomplished by the steroidogenic acute 
regulatory protein (StAR), a transport protein that regulates cholesterol transfer 
from the outer mitochondrial membrane to the inner membrane. Here, cholesterol 
is the substrate of P450scc enzyme, the first enzymatic step in the neuroactive 
steroid synthesis. A) In the diabetic state, we observed a reduced neuroactive 
steroid synthesis in the sciatic nerve due to decreased expression of StAR, P450scc 
and 5α-reductase (5α-R). B) The treatment of diabetic rats with the GW3965, a LXR 
synthetic ligand, restored the expression of the steroidogenic enzymes, and the 
neuroactive steroid levels affected by diabetic neuropathy. Moreover, LXR 
activation also induced the expression of the cholesterol efflux genes such as 
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ABCA1 and ABCG1. In conclusion, the activation of LXRs promotes cholesterol 
utilization and finally protects from peripheral neuropathy-induced diabetes. 
 
With these experiments on neuroactive steroids induction via LXR activation 
we have shown that treatment of diabetic STZ-treated rats with a synthetic 
LXR ligand, promotes steroidogenesis, cholesterol disposal, and raises the 
local levels of neuroactive steroids, resulting in significant improvements in 
thermal nociceptive activity, nerve conduction velocity, and Na+,K+-
ATPase activity. Alltogether these effects are associated with 
neuroprotection against peripheral neuropathy induced by diabetes. 
In addition to their role in the regulation of cholesterol homeostasis, the LXRs 
also modulate FA metabolism. In fact, the LXRs directly regulate expression 
of the lipogenic transcription factor SREBP-1c, and of key enzymes involved 
in FA biosynthesis, such as fatty acid synthase (FAS) and stearoyl-CoA 
desaturase-1 (SCD-1) (Kalaany and Mangelsdorf, 2006, Schultz et al., 2000). 
Due to the ability of LXRs to modulate lipid levels we evaluated the 
potential of a synthetic LXR activator to reverse diabetes-induced lipid 
abnormalities in sciatic nerve myelin. 
Alterations of myelin lipid and protein composition in peripheral nerves are 
often associated with metabolic derangements and neurodegenerative 
disorders, and can result in reduced saltatory conduction of nerve impulses 
throughout the axons (Chrast et al., 2011). Peripheral neuropathy comprises 
functional and structural changes in peripheral nerves, such as a reduction 
in nerve conduction velocity, axonal degeneration, paranodal 
demyelination, and loss of myelinated fibers (Sugimoto et al., 2000, Vinik et 
al., 2000). Some of the morphological alterations in myelinated fibers of 
peripheral nerves associated with hyperglycemia are also seen in rat 
models of STZ-induced diabetic neuropathy (Veiga et al., 2006a). These 
alterations include myelin invaginations in the axoplasm (infoldings) and 
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myelin evaginations in the Schwann cell cytoplasm (outfoldings), as well as 
alterations in myelin compaction such as abnormally wide incisures and 
aberrant separation of myelin lamellae. Similar to those seen in aged 
rodents (Azcoitia et al., 2003), the predominant myelin abnormalities found 
in STZ-treated rats are myelin infoldings (Veiga et al., 2006a).  
We have found that diabetes indeed induces an altered lipid profile in 
myelin. Diabetes results in a concomitant decrease in myelin of cholesterol 
and monounsaturated FAs, and an increase in polyunsaturated FAs, which 
together with changes in phospholipid species and in the desaturation 
(C18:0/C18:1 ratio) and membrane fluidity (C18:1/C18:2 ratio) indexes, may 
be responsible for altered myelin lipid-protein interactions. We also 
observed in the hyperglycemic state a reduction in myelin P0. It appears 
that diabetes modifies myelin’s lipid profile and protein composition, 
changes that result in altered membrane fluidity and myelin abnormalities 
(Verheijen et al., 2009). These data are consistent with papers showing that 
changes in myelin lipid composition in STZ-treated animals correlate with 
altered biophysical properties of the myelin sheath, as assessed by electron 
spin resonance spectroscopy (Zuvic-Butorac et al., 2001). Our principal 
component analysis shows that control and diabetic rats differ in the lipid 
composition of myelin. The differences may be the result of decreased 
expression of genes involved in FA biosynthesis, as most of them are 
downregulated by DPN. Furthermore, these changes were associated with 
increased myelin abnormalities and reduced performance of diabetic 
animals in functional tests. While STZ-diabetic animals show profound 
differences in body weight and nutritional status compared with control 
rats, plasma lipids do not show the altered profile seen in myelin lipids, 
suggesting that DPN has a specific impact on peripheral nerve lipid 
synthesis. Because insulin is a known activator of SREBP-1c transcription, the 
lack of insulin in STZ-treated rats may account for the observed reduction of 
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nuclear, active SREBP-1c (Chen et al., 2004). It has been reported that 
insulin activates SREBP-1c and FAS promoter activity directly in rat-isolated 
Schwann cells, indicating that this hormone regulates lipid metabolism in 
peripheral nerves (de Preux et al., 2007). The role of this regulatory pathway 
in peripheral nerves is still unclear; nevertheless, its downregulation 
contributes to the pathogenesis of DPN. Thus, it may be possible that insulin 
administration, by activating SREBP-1c and FA synthesis, could ameliorate 
the altered myelin lipid and protein pattern induced by diabetes. The 
response to insulin requires two LXR binding sites in the promoter of SREBP-
1c; disruption of these LXR binding sites does not lower basal transcription 
but severely reduces the transcriptional induction induced by insulin (Chen 
et al., 2004). In our diabetic model, to reactivate SREBP-1c, we decided to 
use a selective LXR ligand rather than insulin itself because in addition to its 
ability to induce SREBP-1c expression, insulin can also reduce systemic 
glucose levels, and thus obscure the specific effects due to exclusive 
activation of SREBP-1c. LXR activation in diabetic rats restored expression of 
key genes of FAS synthesis and brought myelin lipid content back to control 
levels. These beneficial effects of LXR activation are probably due to LXR’s 
ability to restore the levels of nuclear-active SREBP-1c. Treatment with 
synthetic LXR ligands also brought back to normal the levels of myelin P0. 
Whether this is due to SREBP-1c activation, or to changes in myelin lipid 
content that influence protein packaging in this membrane, remains an 
open question. Because neuroactive steroids enhance P0 expression 
(Melcangi et al., 2005) and LXR activation also increases neuroactive 
steroid levels in sciatic nerve, it is possible that the beneficial effects of LXR 
activation on P0 levels are due to greater concentration of neurosteroids. 
LXR activation also restored myelin structure to that seen in nondiabetic rats 
and improved performance of treated animals in functional tests. These 
improvements were seen in the absence of side effects that have been 
associated with LXR-SREBP-1c activation, such as hepatic steatosis (data 
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not shown). This is probably the result of our very mild, but effective, dosing 
regimen. It is interesting to note that LXR double knockout mice exhibit 
thinner myelin sheaths in peripheral nerves (Makoukji et al., 2011). These 
observations highlight the significance of the LXR-SREBP-1c axis in the 
control of myelin lipid content, and suggest that synthetic LXR activators 
may be useful to reverse myelin abnormalities brought about by diabetes.  
Our first study demonstrated that DPN causes a decrease in the levels of 
dihydroprogesterone (DHP) and 3α-diol in the peripheral nerves. DHP and 
3α-diol exert protective actions in a rat model of DPN, by mechanisms that 
still remain not fully characterized. Then, we demonstrated that LXR 
activation is able to ameliorate the peripheral neuropathic phenotype in 
diabetic rats acting on lipid metabolism and the protective effects has also 
been proved to be coupled with the restoration to non-diabetic control 
values of DHP and 3α-diol levels in peripheral nerves.  
The experience gained with LXR activation on DPN together with the 
protective effects of neuroactive steroids so far ascertained (Melcangi and 
Panzica, 2009) led us to evaluate whether DHP or 3α-diol may act on DPN 
by influencing myelin lipid profile, through the regulation of fatty acid 
biosynthetic pathway and ultimately protecting myelin structure and 
function. 
Our data show that DHP and 3α-diol, in the context of DPN, modulate 
directly the de novo lipogenic pathway. Thus, both neuroactive steroids are 
able to almost fully restore the altered myelin lipid profile to the levels of 
non-diabetic controls consequently improving myelin morphology.  
Defects in desaturation are considered responsible for alterations in myelin 
structure and function (Garbay et al., 2000, Verheijen et al., 2009). Stearic 
acid (C18:0) and oleic acid (C18:1) are the most abundant fatty acids 
associated to phospholipids in the peripheral myelin of rats and mice. The 
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levels of these two most representative fatty acids in the myelin of the 
sciatic nerve were altered by diabetes and restored to control values by 
DHP or 3α-diol treatment. Moreover, oleic acid (C18:1) is produced by 
desaturation of the saturated stearic acid (C18:0), a biochemical reaction 
catalyzed by the stearoyl-CoA desaturase-1 (SCD-1). Stearic acid (C18:0) is 
either synthesized in the body from palmitic acid (C16:0) by elongation or 
ingested directly with the diet. In our study, Palmitic acid (C16:0) levels in 
myelin were not affected, indicating that the observed accumulation of 
stearic acid (C18:0) detected in the myelin of diabetic rats was due to an 
impaired desaturation of stearic acid (C18:0). In this regard, the most 
important outcome of the DHP or 3α-diol treatment is their ability to bring 
back the expression levels of SCD-1 to control values, thus restoring the 
desaturation of stearic acid (C18:0) to oleic acid (C18:1). Consequently, 
steroids treatment also normalizes the desaturation and possibly the 
membrane fluidity indexes. 
Cholesterol is a molecule required for myelin stabilization and compaction 
(Nussbaum et al., 1969, Detering and Wells, 1976) and plays an essential role 
in coordinating myelin membrane assembly. Indeed, the inactivation of 
cholesterol biosynthesis in Schwann cells led to substantial hypomyelination 
(Saher et al., 2005). In the present study in diabetic animals, we did not 
detect hypomyelination (see g-ratio data in Fig. 19) but myelin infoldings, 
most probably associated to changes in membrane fluidity (as suggested 
by the ratio of C18:1/C18:2). This is likely the result that diabetes was 
induced in adult animals and not as in the conditional inactivation of 
squalene synthase in mice occurring from birth or before (Saher et al., 
2005). On this basis, it seems that the restoration of fatty acid desaturation 
by the DHP or 3α-diol treatments, which were unable to restore cholesterol 
levels, is one the main phenomenon required to protect myelin lipid profile 
from alterations induced by diabetes. 
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In conclusion, as summarized in Figure 25, our findings indicate that 
treatments with DHP and 3α-diol are able to modulate the lipogenic 
pathway and to normalize the lipid species in the peripheral myelin of 
diabetic rats, resulting in protection against DPN. 
 
           
 
Figure 25: Proposed model of the protective effects exert by DHP and 3α-diol in 
diabetic peripheral neuropathy. A) In diabetic conditions de novo lipogenesis is 
reduced and stearic acid (C18:0) is accumulated while its corresponding 
desaturated fatty acid such as the oleic (C18:1) is reduced. These situations favor 
the myelin infoldings. B) The treatments with DHP or 3α-diol normalized lipogenesis 
and improved the desaturation of stearic acid (C18:0) into oleic acid (C18:1), the 
two most abundant fatty acids present in purified myelin. 
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 Finally, the regulation of myelin proteins by neuroactive steroids (Pesaresi et 
al., 2011) and the modulation of myelin fatty acid species by the same 
molecules suggest that both pathways are strictly interconnected and 
required for proper myelin structure and function. 
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